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Summary 
Malignant mesothelioma (MM) is an aggressive cancer, the consequence of which is 
neoplastic transformation of mesothelial cells and is strongly associated with 
previous asbestos exposure. The disease is associated with poor patient survival due 
to difficulties in diagnosis and treatment options currently available. Therefore, it is 
essential to identify novel molecular targets that can be used to develop new 
treatment opportunities. Hedgehog (Hh) and transforming growth factor-beta (TGF-
β) signalling pathways are involved in numerous overlapping developmental 
processes as well as tissue repair and tumorigenesis.  Recently, TGF-β has been 
shown to induce the expression of Hh signalling effector molecules, the Gli 
transcriptional factors in various cancer cell types. Our laboratory has been interested 
in assessing the interaction between the TGF-β and Hh signalling pathways and how 
this interaction may contribute to tumour growth and metastasis in MM.  
This study will test the hypothesis that TGF-β induces Gli1 and Gli2 expression in 
MM cells through activation of the SMAD signalling pathway. To test the 
hypothesis, this study addresses three aims. Aim 1, to examine the effect of TGF-β 
on Gli expression. Aim 2, to determine if TGF-β-induced Gli mRNA is independent 
of the Hh signalling pathway and to examine the effects of blocking TGF-β on Gli 
mRNA levels and aim 3, to determine the signalling pathway through which TGF-β 
regulates Gli expression. 
MM and control mesothelial cells all expressed variable amounts of basal TGF-β1 
and TGF-β2 mRNA with most MM cells expressing quantitatively higher TGF-β1 but 
lower TGF-β2 mRNA than controls. Basal levels of Gli1 and Gli2 mRNA were 
variable across the cell lines but Gli2 was upregulated in all cells upon TGF-β2 
stimulation. TGF-β1 had no effect on Gli1 or Gli2 mRNA levels and TGF-β2 had no 
effect on Gli1 mRNA levels. These findings are different to previous studies in 
different cancers where TGF-β1 has been shown to upregulate early expression of 
Gli2 mRNA and subsequent upregulation of Gli1. This is the first time the effect of 
TGF-β2 has been examined in any cell line.   
The mechanism of TGF-β2-mediated Gli2 mRNA expression was also examined 
using pharmacological inhibitors to the type I TGF-β receptor ALK5, and siRNA 
  
 
iv 
against key mediators of the TGF-β SMAD signalling pathway, SMAD2 and 
SMAD3. Inhibition of ALK5 and SMAD2 and SMAD3 inhibited TGF-β2-induced 
Gli2 expression, confirming that TGF-β2-mediated Gli2 expression is SMAD2/3 
dependent. Further studies are required to determine if TGF-β2-mediated Gli2 
expression is independent of the classical Hh signalling Patched/Smoothened 
(Ptch/SMO) receptor complex.  
In conclusion, TGF-β2 was identified as a potent transcriptional inducer of Gli2 
transcription factor. These findings may be valuable in providing new therapeutic 
opportunities to treat MM using targeted TGF-β and Gli therapies. Further studies 
are now required to examine the functional importance of TGF-β2-mediated Gli2 
expression in MM cell function and tumour growth. 
In conclusion, TGF-β2 was identified as a potent transcriptional inducer of Gli2 
transcriptional factor. These findings may be valuable in providing new therapeutic 
opportunities to treat MM using targeted TGF-β2 and Gli2 therapies. However, to 
make a definitive conclusion about this aspect, further studies need to be completed 
examining their functional importance in MM tumour growth. 
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1.1 Introduction 
The mesothelium comprises a monolayer of mesothelial cells extending over the 
surface of the serosal cavities and organs (Whitaker, Papadimitriou & Walters, 
1982), with a main functional role of providing frictionless free movement between 
these tissues and organs, as well as protecting from infection and injury (Yung & 
Chan, 2007). Malignant transformation of mesothelial cells is closely linked to 
asbestos exposure (Spugnini, Bosari, Citro, Lorenzon, Cognetti, Baldi, 2006), and 
leads to the development of malignant mesothelioma (MM) (Mutsaers, 2004), MM 
an aggressive cancer with a poor prognosis. It has been well established that  MM is 
largely unresponsive to traditional cancer treatments such as chemotherapy or 
radiation (Spugnini et al., 2006) and therefore novel therapeutic approaches are 
required. 
 
In recent years the role of developmental signalling pathways has become an 
important focus of research in certain cancers and increasing evidence implicates the 
reactivation and aberrant expression of these pathways as critical to their 
pathogenesis. Two of these pathways are the hedgehog (Hh) and transforming 
growth factor β (TGF-β) signalling pathways. Both pathways have been individually 
studied in various cancers, however the molecular and cellular mechanisms behind 
their regulation of tumour growth are still unclear. Recent evidence has demonstrated 
a link between these pathways, and how they may work together to promote tumour 
growth and metastases in various cancers including gastric, breast and pancreatic 
adenocarcinomas. This current study will examine the interaction between the Hh 
and TGF-β signalling pathways in MM. The emerging picture of Glioma-associated 
oncogene homologue (Gli) transcription factors as an integrative platform of 
signalling pathways could have important implications in understanding tumour 
growth and development. Thus, examining how these pathways interact will expand 
the current understanding of the growth and development of this disease which may 
open new avenues for therapeutic approaches against MM progression. 
 
 
 
  
 
3 
1. 2 The mesothelium 
1.2.1 Structure 
The mesothelium is derived from mesodermal tissue and extends over the entire 
surface of the pleura, pericardial and peritoneal surfaces (Mutsaers, 2004; Whitaker 
et al., 1982) and lines the sac that surrounds the testes (Mutsaers, 2004). The cells are 
25µm in diameter and predominantly flattened, squamous like with surface 
microvilli resting on a thin basement membrane supported by connective tissue 
stroma and are present in greater numbers on the visceral (outer) surfaces compared 
to the parietal (inner) surfaces, Figure 1.1 & 1.2 (Whitaker et al., 1982). 
 
 
 
 
 
Figure 1.1: A double layered mesothelium (arrows) on the visceral serosa of the lung 
of a 4 ½ week old human embryo (magnification x 500) (reproduced from Whitaker 
et al., 1982). 
 
Despite the fact that the mesothelium is mainly composed of flattened cells, cuboidal 
cells can also be found in the milky spots of the omentum, within the septal folds of 
the mediastinal pleura and on the peritoneal side of the diaphragm overlying the 
lymphatic lacunae (Whitaker et al., 1982).  
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Figure 1.2: Electron micrograph of luminal aspect of mesothelium covered with a 
carpet of microvilli. Bar 3.2 µM (reproduced from Mutsaers, 2004). 
 
1.2.2 Function 
Although the structural organisation of the mesothelium indicates that it is a simple 
tissue, its functions are quite complex. The major functional roles of the mesothelium 
is to serve as a protective barrier against abrasion and infection, and to provide a 
frictionless interface to facilitate the free movement of opposing tissues and organs 
(Mutsaers, 2004). Tight junctions bind the mesothelial cells together. Secreted 
surface glycosaminoglycans, proteoglycans and surfactant lubricants secreted by the 
mesothelial cells, provide a non-adhesive glycocalyx and fluid lining that protects the 
serosal surface from abrasive damage and infection (Mutsaers, 2004; Whitaker et al., 
1982).  
 
Compelling evidence also highlights the importance of the mesothelium immune 
surveillance, where the mesothelium can initiate a specific immune response against 
an invading agent (Yung & Chan, 2007).  The mesothelium can also transport fluid 
and solutes across the serosal membrane through pinocytic vesicles, intracellular 
junction and stromata (supporting framework of a cell), which allows rapid removal 
of fluid and cells from the serosal cavities to the underlying lymphatic system (Yung 
& Chan, 2007). In addition to these function, the mesothelial cells participate in 
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initiating and resolving serosal inflammation and repair, preventing adhesion 
formation through lysis of fibrin deposits and providing protection (a process of the 
immune system whereby cells capture antigen and enable their recognition by T-
cells) against invading microorganisms (Mutsaers, 2004). The mesothelium also 
performs other functions that are essential for serosal homeostasis such as antigen 
presentation, synthesis of inflammatory growth factors and mediators (Mutsaers, 
2004; Yung & Chan, 2007) and an active role in fibrin deposition and clearance 
(Yung & Chan, 2007).  
 
1.3 Malignant Mesothelioma 
MM is classified by its histological appearance, and according to the World Health 
Organization (WHO), this classification is in four main types; epithelioid, 
sarcomatoid, desmoplastic and biphasic (Izzi, Masuelli, Ttesoldi, Foti, Modesti & 
Bei, 2012). Patients with epithelioid MM often survive longer, while sarcomatoid 
MM is associated with poor prognosis (Sekido, 2010). The most important risk factor 
associated with MM is exposures to silicate asbestos fibres, but simian virus 40 
(SV40) and genetic predisposition have also been linked to the disease (Husain et al., 
2009). MM is resistant to chemotherapy and radiation therapy; in addition, current 
therapeutic approaches have so far proven to be ineffective to halt disease 
progression (Spugnini et al., 2006). 
Malignant pleural mesothelioma (MPM) is the most common form of MM, followed 
by peritoneal malignant mesothelioma (PMM), then pericardial MM (Sekido, 2010).  
MPM patients commonly present with a pleural effusion associated with chest pain 
and dyspnoea (Boutin, Schlesser, Frenay, & Astoul, 1998). PMM is often found as a 
large tumour mass on the omentum, or as a diffuse tumour of the intestinal serosa 
(Moore, Parker & Wiggins, 2008). PMM presents with nonspecific symptoms 
including nausea, vomiting, constipation, diarrhoea and loss of appetite, with small 
bowel obstruction a late feature (Moore et al., 2008; Spugnini et al., 2006). 
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1.3.1 Epidemiology 
MM before 1950 was so rare that pathologists questioned its existence (Garlepp & 
Leong, 1995). Wagner and colleagues established the link between asbestos and MM 
in 1960 based on the epidemiological data from South Africa (Wagner, Sleggs & 
Marchand, 1960). In Australia, the first reported case of MM was in a Wittenoom 
worker in 1962 and reports from other Australian states followed thereafter 
(McNulty, 1962). Although the use of asbestos was widely abandoned around 1980’s 
in the western world, the long latency period between the exposure to asbestos and 
the onset of MM, which can range from 15 to 60 years, meant that the mortality rates 
from MM have continued to rise (Moore et al., 2008). The occurrence of MM is 
higher in males (70-80%) than in females, and the diagnosis of the disease is usually 
made 20 to 40 years following exposures to asbestos (Moore et al., 2008). Based on 
this, the worldwide incidence of MM is predicted to peak in the next 20 years (Rudd, 
2010). However, in non-western and developing countries where asbestos was used 
later then in western countries in some cases is still being used, there is a predicted 
corresponding delay in the anticipated peak incidences of MM (Leigh, Davidson, 
Hendrie, & Berry, 2002).  
 
1.3.2 Aetiology 
Asbestos refers to a group of naturally occurring hydrated mineral silicate fibres 
(Moore et al., 2008). The two main forms are serpentine asbestos; represented by 
chrysotile (white asbestos), and amphibole asbestos; which includes crocidolite (blue 
asbestos), amosite (brown asbestos), actinolite, tremolite and antheophyllite, (Rudd, 
2010). Crocidolite, comprising of long thin fibres, are considered to be the most 
oncogenic type of asbestos fibre because they are able to penetrate the lungs resulting 
in repeated damage and tissue repair as well as local inflammation (Sekido, 2008). 
The action of asbestos fibres in the pathogenesis of MM is still unclear, but the 
toxicity of most asbestos is dependent on the chemical and physical properties of the 
fibres and the time from the initial exposure (Kamp, 2009). Other factors such as 
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genetic predisposition are also likely to impact on the development of MM (Sekido, 
2008). For example, studies examining Turkish families from three different villages, 
showed a cluster of MM cases with an autosomal dominant pattern, suggesting a 
possible genetic cause for the disease (Dogan, Baris, & Dogan, 2006).  
SV40 is a DNA virus found in both monkeys and humans which can induce tumour 
development by blocking tumour suppressor genes (Rudd, 2010). SV40 virus has 
been proposed as an etiological agent for MM, but although its role in MM 
pathogenesis remains controversial (Murthy & Testa, 1999). It is thought to have a 
strong co-carcinogenic effect when associated with asbestos (Murthy & Testa, 1999). 
 
1.3.3 Pathogenesis 
MM induced by asbestos is thought to occur in four main processes. Firstly, asbestos 
has the ability to penetrate deeply into the serosal cavities and is thought to 
contribute to mechanical injury to the mesothelial cells which than initiates repeated 
cycles of damage, repair and inflammation (Rudd, 2010). Secondly, asbestos fibres 
may pierce the cells and disrupt the mitotic spindle of cells, affecting mitosis which 
may result in chromosomal damage such as aneuploidy (Sekido, 2010). Loss of 
chromosomes in MM, such as chromosome 22, causes aberrant or no expression of 
the Neurofibromatosis type 2 (NF2) tumour suppressor gene (Murthy & Testa, 
1999). It has been noted that NF2 gene is inactivated by homozygous deletion, 
missense or nonsense mutations in 40-50% of MM cases (Sekido et al., 1995). A 
recent study has demonstrated that somatic mutations in the BAP1 (BRCA 1-
associated protein 1) gene caused by the loss of an allele at 3p21 region, was found 
in 23% of MM patients (Rascoe, Jupiter, Cao, Littlejohn, & Smythe, 2012).  Thirdly, 
asbestos can cause DNA strand breaks mediated by iron catalysed free radicals. 
Asbestos causes the release of reactive oxygen species (ROS) and nitrogen species 
(NOS), which can directly induce genotoxicity including base deletions, 
substitutions, insertion, sister chromatid exchange, rearrangements and chromosomal 
aberrations (Kamp & Weitzman, 2009). These may then lead to mutations in the 
mammalian cells, and subsequently the cell transforms and is able to resist apoptosis 
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and undergo transformation (Kamp & Weitzman, 2009). Recently, Shukla et al, 
(2009) proposed that asbestos causes mesothelial cell death, primarily through 
programmed necrosis, involving H₂O₂ secretion, ATP depletion and high-mobility 
group box 1 protein (HMGB1) release, thereby promoting an inflammatory response. 
Fourthly, asbestos fibres induce the persistent activation of signalling pathways such 
as ERK1/2 involved in cell proliferation, protein metabolism and signal transduction, 
which are significantly altered in mesothelial cells after asbestos exposure (Kamp & 
Weitzman, 2009). Recent studies demonstrated critical roles for tumour necrosis 
factor-alpha (TNF-α) and nuclear factor-kB (NF-kB) in MM pathogenesis (Yang et 
al., 2006). Following asbestos exposure, macrophages accumulate in the pleura and 
lungs that secrete TNF-α, which binds to its receptor TNF-R1 and activates the NF-
kB pathway. This activation allows mesothelial cells with asbestos induced DNA 
damage to divide rather than die, eventually developing MM (Yang et al., 2006). In 
addition to TNF-α, other cytokines and growth factors have been implicated in 
asbestos carcinogenesis, and their role in MM pathogenesis is being investigated 
(Sekido, 2010). Examples include: transforming growth factor-β (TGF-β), 
interleukin (IL) 6 and 8, which may have a role in stimulating tumour growth, and 
platelet derived growth factor (PDGF), which might act as regulatory factor in MM 
cell proliferation (Shukla et al., 2009).  
 
1.3.4 Current Treatments 
MM has a poor prognosis with an inevitable fatal course and very few long term 
survivors. MM cells have shown particular resistance to current available 
chemotherapy treatments with a median survival of 8 to 12 months and less than 
20% response rate. Single line therapy (recommended initial treatment for MM) has 
not been successful. To date, the combination of pemetrexed and cisplatin has 
yielded the best results, with 12.1 months survival rate, and 41% response rate in a 
phase III clinical trial (Vandermeers et al., 2009). However, these agents interfere 
with the cell division process and in turn activates apoptosis (Spugnini et al., 2006), 
and the major concern with this treatment is rapid relapse, acute toxicity and shorter 
response duration. Radiation therapy has also been ineffective in prolonging patient 
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survival. However, some studies have shown gross disease regression after radiation 
therapy (Gregoire, 2010). In some studies, surgery has had beneficial responses with 
pleurectomy and extrapleural pneumonectomy (EPP). The most effective 
pleurectomy involves removal of the parietal (lines the inner pleural cavity and 
covers the diaphragm) and/or visceral (a thin serosal membrane around the inner 
walls of the lungs) pleura, leaving the underlying lung. EPP involves removal of the 
entire pleural envelop and its content as well as the affected lung, diaphragm and a 
portion of the pericardium. However, both pleurectomy and EPP have not 
consistently been shown to significantly prolong MM patient survival (Sugarbaker, 
Heher & Lee, 1991).  
 
In general, therapeutic options including surgery, radiation, chemotherapy, 
immunotherapy and gene therapy, have had limited success to date. Therefore, 
current research is focussing on targeted molecular therapeutic approaches. Gene 
mutations and accumulation of these mutations, together with aberrant activation of 
growth regulatory pathways, has been linked to many cancers including MM. Hence, 
a better understanding of the underlying mechanisms regulating MM growth will 
help to identify molecular targets that can be used for diagnosis, prognosis and 
therapies. This is critical for many Australians with past asbestos exposure who have 
an increased future risk of developing MM. 
 
1.4 Role of signalling pathways in MM 
There has been a lot of interest in recent years in the role of cell signalling pathways 
in cancer. In particular the reactivation of classical developmental signalling 
pathways’, and their role in the early event of cell transformation. Reactivation of 
these pathways leads to various processes such as cell cycle regulation, apoptosis and 
angiogenesis. There is also increasing evidence of aberrant activation of these 
pathways. It is evident that distinct epigenetic and genetic events characterize the 
interplay between the molecules involved in these pathways. Involvement of the 
cytokine TNF-α and molecular pathway NF-kB in MM have been briefly described 
earlier. Similarly, studies have shown the involvement of other growth factors and 
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molecular pathways linked to MM, among these is TGF-β together with Ras, Hippo 
and Wnt signalling pathways (Zucali, Ceresoli, De Vincenzo, Simonelli, Lorenzi, & 
Gianoncelli, 2011). Another pathway, the Hedgehog pathway, has clearly been 
associated with tumorigenesis, with mutations in this pathway leading to 
hyperactivation of the pathway identified in a variety of cancers. However, its 
reactivation and aberrant activation in the growth and development in MM remains 
to be determined. In addition, recent evidence has shown crosstalk between the Hh 
and TGF-β signalling pathways. Several studies have shown that TGF-β can 
upregulate the important Hh pathway effector molecule Glioma-associated oncogene 
homologue (Gli) (Zucali et al., 2011). As we know that TGF-β is an important 
molecule for MM growth, studies into the interaction of these pathways in MM may 
identify novel therapeutic approaches to treat this disease. 
 
 
1.5 The Hedgehog signalling pathway in development 
Complex body plans requires the involvement of cell-cell signalling pathways.  The 
discovery of the Hh gene was made through a genetic screen of mutations that 
disrupt the Drosophila larval body plan (Nusslein-Volhard & Wieschaus, 1980). The 
gene mutation resulted in disruption to the dorsal-ventral body plan of the larva 
leading to an abnormal distribution of hair-like projections on its ventral surface, 
called denticles. These hairs are distributed at regular intervals forming bands across 
the ventral surface and they appear along the entire length of the larva. The gene 
mutation identified by Nusslein, Volhard and Wieschaus lead to ectopic production 
of denticles on the ventral surface leading to the physical appearance of the larva that 
resembled that of a hedgehog. Thus, the gene and subsequent signalling pathway was 
given the name Hedgehog signalling pathway (Ingham & McMahon, 2001). Hh is a 
secreted protein that acts as an intercellular signalling protein. Hh proteins have been 
identified in a range of vertebrate species that function as key mediators of many 
fundamental processes. There are three mammalian Hh genes activating the same 
canonical signalling pathway, and these are sonic hedgehog (Shh), dessert hedgehog 
(Dhh) and indian hedgehog (Ihh) (Ingham & McMahon, 2001). Shh is the most 
extensively studied ligand that has not only been associated with developmental 
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processes but also more recently has been implicated in some disease processes in 
man (Watkins, Berman, Burkholder, Wang, Beachy & Baylin, 2003).  
 
 
1.5.1 Biological function 
The Hh family of intercellular signalling proteins have been recognised as key 
mediators of several fundamental processes in embryonic development (Ingham & 
McMahon, 2001). The activities of these proteins are critical to the growth, 
morphogenesis and patterning of many different regions within the body plans of 
insects and vertebrates, and in most invertebrates (Ingham & McMahon, 2001). In 
embryonic development of a Drosophila, Hh is a central patterning signal in the 
wing, eye discs and leg (Herberlein, Singh, Luk, & Donohoe, 1995), together with 
regulating other processes such as germ cell migration, development of gonad, 
abdomen, tracheal system and optic lamina (Glazer & Shilo, 2001). Hh genes have 
also been identified in other species such as sea urchin and leech (Chang, Lopez, 
Von Kessler, Chiang, Simandl, Zhao, 1994). In vertebrate embryos, Shh expression 
has been observed in three key signalling centres, the floor plate, notochord and the 
zone of polarizing activity (ZPA), during limb bud development (Ingham & 
McMahon, 2001). The importance of notochord and floor plate is in the 
ventralization of the developing neural tube, whereas the ZPA plays a role in 
regulating anterior polarity (Ingham & McMahon, 2001). This suggests that the 
discovery of Shh provided an insight into neural tube and limbs formations thus, 
suggesting a molecular link in the development of distinct vertebrate body plans. In 
general, Shh signals can regulate cell proliferation, cell fate specification, and cell 
survival by inducing the expression of a range of target genes. For instance, Shh in 
blood cells plays a role in stem cell proliferation, thrombocyte differentiation and 
activation of haematopoiesis (Dyer, Farrington, Mohn, Munday & Baron, 2001). In 
the heart, Shh controls cardiac morphogenesis (Zhang, Santos & McMahon, 2001). 
In the limbs, Shh regulates anterior-posterior patterning of the skeleton (Dyer et al., 
2001). In the lungs, Shh controls branching epithelium together with proliferation 
and survival of mesenchyme cells (Pepicelli, Lewis & McMahon, 1998). Shh also 
controls growth and morphogenesis in prostate and tooth (Ingham & McMahon, 
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2001). Crucial developmental functions of  Hh signalling in embryonic development 
is illustrated by defects in this pathway, which results in several foetal abnormalities 
in the brain, facial and midline (Belloni, Muenke, Roessler, Traverso, Siegel-Bartelt, 
& Frumkin, 1996). These defects are defined in holoprosencephaly, microencephaly 
and cyclopia (Gupta, Takebe & LoRusso, 2010). Holoprosencephaly is a disorder 
involving the development of midline and forebrain, in which the ventral cell types 
are lost, and in humans is caused by mutations that lead to Shh activity (Belloni et 
al., 1996). 
 
In adults, the Hh pathway remains active, and is particularly involved in regulating 
tissue homeostasis and in continuous renewal and repair processes of adult tissues 
(Ingham & McMahon, 2001). The Hh pathway also plays a critical role in adult stem 
cell maintenance (Hooper & Scott, 2005). Most of the renewing tissues, such as skin 
and bone marrow, are maintained by stem cells that demonstrate the ability to both 
give rise to mature cell types of that specific tissue and to generate additional stem 
cells. The Hh signalling regulates stem cell activity through stimulating proliferation 
and self-renewal of stem cells in various tissues ((Reya, Morrison, Clarke & 
Weissman, 2001). 
 
 
1.5.2 Signal Transduction 
Hh signal transduction is induced after the initial modification of the Hh ligands. The 
Hh proteins are synthesised as 45kD precursor proteins that undergo intramolecular 
cleavage (Lee, Ekker, Von Kessler, Porter, Sun & Beachy, 1994). This modification 
is through the autocatalytic cleavage of the C-terminal domain, combined with 
binding of a cholesterol moiety at this cleavage site (Mahindroo, Punchihewa & Fuji, 
2009). In addition to cholesterol coupling, the ligand is further lipid modified via 
palmitoylation of the N-terminal cysteine, giving rise to the active form of the Hh 
ligand (Ingham & McMahon, 2001). In embryonic development, the cells 
synthesizing Hh ligands are distinct from the Hh responsive cells that may be either 
situated adjacent to, or at some distance from the Hh secreting cell (Varjosalo & 
Taipale, 2007).  
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In certain conditions the Hh secreting cells release Hh ligands into the extracellular 
environment. They can then bind to the 12-span transmembrane protein receptor 
Patched (Ptch) located on the surface of the Hh responsive cell that function as a 
platform for intracellular signal transduction (Rietveld, Neutz, Simons & Eaton, 
1999). In the absence of the Hh ligand, Ptch normally associates with the seven-
transmembrane span receptor-like protein Smoothened (Smo) at the cell membrane 
and this interaction leads to inhibition of Smo dependent downstream intracellular 
signalling (Ingham & McMahon, 2001). This inhibition leads to phosphorylation of 
the glioma associated (Gli) zinc finger transcription factors that function downstream 
of the Smo receptor. In vertebrates there are three distinct Gli proteins, Gli1, Gli2 and 
Gli3 (Hui, Slusarski, Platt, Holmgren & Joyner, 1994), where Gli1 and Gli2 proteins 
activate Hh target genes functioning as transcriptional activators, and Gli3 is thought 
to act mainly as a transcriptional repressor (Choi, Omenetti, Syn & Diehl, 2010). 
Gli2 is the primary mediator of Hh signalling, as genetic approaches show the 
precedent role of Gli2 in Hh signalling for the induction of the Gli1 transcription 
factor (Choi et al., 2010). 
 
The Gli proteins are phosphorylated in the cytosol by protein kinase A (PKA), 
glycogen synthetase kinase 3 (GSK3) and casein kinase (CSK) that targets them for 
degradation in the cytosol by proteasomes, preventing their nuclear translocation and 
transcription of the Hh target genes (Pan, Bai, Joyner & Wang, 2006; Pan, Wang & 
Wang, 2008). 
 
On the other hand, when the extracellular environment of the responsive cell is 
enriched with Hh ligands, the Hh pathway is activated and the Hh ligand binds to the 
Ptch receptor and this releases Smo leading to its activation (Metcalfe & De Sauvage, 
2011). Activation of Smo prevents the phosphorylation of Gli transcription factors, 
allowing their nuclear translocation and induction of transcription of Hh target genes 
such as sfrp2, neo1 and c-myc (Pan et al., 2006; Pan et al., 2008).  
 
In vertebrates, in the presence of Hh ligand, the mechanism by which the Hh signal is 
transmitted from Smo to Gli transcriptional factors is not well understood. However 
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in flies, the Hh ligand binding leads to localisation of Smo, and involves complexes 
such as the serine threonine kinase fused (Fu), suppressor of fused (sufu) and 
kinesin-like molecule Costal-2 (cos2) (Ogden, Ascano, Stegman, Suber, Hooper & 
Robbins, 2003). The details of Gli activation remain obscure, however evidence 
suggests that in the absence of the Hh ligand, Gli interacts with multiprotein 
complexes such as sufu, but upon ligand binding the Gli proteins translocate to the 
nucleus initiating transcription (Figure 1.3, Ogden et al., 2003). This shows that the 
Hh signalling is regulated by positive and negative feedback mechanisms that are 
tightly conserved across species (Ingham & McMahon, 2001). Despite this, it seems 
to differentiate at some point amongst vertebrates and invertebrates (Varjosalo, & 
Taipale, 2006). Vertebrates have an additional transmembrane protein, the Hedgehog 
interacting protein (Hhip), which is also a Hh target gene. Hhip was discovered by 
screening mouse complementary DNA (cDNA) expression libraries for proteins that 
bind to Shh (Olsen et al., 2004). The Hhip competes with Ptch for binding to Hh 
ligands, that is, it has an affinity equal to Ptch (Olsen, Hsu, Glienke, Rubanyi & 
Brooks, 2004). Thus, when Ptch levels exceed that of Hh ligand, or when Hhip 
sequesters Hh ligands, this can inhibit the Hh pathway (Olsen et al., 2004). 
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Figure 1.3: the active and inactive states of the Hh signalling pathway. In the 
absence of the Hh ligand, inactive state (left), Ptch inhibits Smo, thus Gli is prevented 
from entering the nucleus through interactions with cytoplasmic protein complexes 
such as fused and sufu, and therefore transcription of the Hh target genes is 
repressed. In the presence of Hh ligand, active state (right), binding of the Ptch to 
Smo is released, leading to translocation of Gli to the nucleus, and Gli activates 
transcription of the Hh target genes (reproduced from Magliano & Hebrok, 2003) 
 
Recent studies in vertebrates have shown that Hh signalling requires a non-motile 
cilium (Huangfu & Anderson, 2005). This was supported by genetic studies in mice 
which showed that disruption of several anterograde or retrograde intraflagellar 
transport components lead to limb and neural patterning defects caused by impaired 
Hh signalling between Smo and Gli (Huangfu & Anderson, 2005). This provides 
compelling evidence that activated mutations in these pathway components would 
increase cell proliferation, a hallmark of tumour formation. 
 
Although the role of Hh signalling in embryonic development is well established, its 
functions in adult tissue repair and maintenance remains unclear. Additionally, 
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several reports indicate that Hh signalling is an important regulator of stem cell 
differentiation and maintenance.  
 
 
1.5.3 Hh signalling and stem cells 
A fundamental characteristic of stem cells is their ability to self-renew and generate 
differentiated cells within different organs (Liu, Dontu, & Mantle, 2006). A number 
of developmental pathways including Hh signalling have emerged as potentially 
regulating the self-renewal processes of normal stem cells in the skin, breast, nervous 
system and other haematopoietic systems (Taipale & Beachy 2001). Han et al. 
(2008) indicated that Hh signalling via the primary cilia was essential for the 
proliferation and maintenance of adult neural stem cells. Liu et al. (2006) studied the 
role of Hh signalling for stem cell self-renewal and multilineage differentiation in 
mammary glands. In normal breast development stem cells are capable of generating 
epithelial components of the mammary gland. They showed that the Hh signalling 
components Ptch, Gli1 and Gli2 were highly expressed in these human mammary 
stem or progenitor cells using both in vitro cell cultivation and in vivo mouse 
xenografts methods. Subsequently, they also showed that these genes were down 
regulated when the progenitor cells were induced to differentiate. 
 
The function of Hh signalling in the haematopoietic system was well demonstrated 
by Zhao et al. (2009) whereby the Hh signalling receptor/modulator Smo was deleted 
in haematopoietic cells and injected into mice to examine the effect. The mice 
showed clear long term defects in the haematopoietic system. This loss of function 
clearly identified the requirement of Smo and Hh signalling in the haematopoietic 
cell self-renewal process in vivo. Forbes et al. (1996) identified that Hh protein is 
produced by the cap cells which controls the maintenance of somatic follicle stem 
cells. Subsequently, in another study conducted by Michel and colleagues (2012) 
they showed that Hh is an essential niche signal for maintenance and differentiation 
of somatic stem cells in the testis of a Drosophila.  
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1.5.4 Hh pathway and cancer 
Hh genes can induce cell proliferation, and this function of the Hh pathway 
signalling is important in embryogenesis and tissue maintenance, but inappropriate 
Hh pathway activation can lead to tumorigenesis. In recent years, it has become clear 
that the aberrant activation of the Hh signalling pathway can lead to cancer, whereby 
abnormal upregulation of the Hh ligand or deregulated expression of downstream Hh 
pathway mediators is demonstrated. For example, loss of Ptch1 protein (Gailani, 
Stahle-Backdahl, Leffell, Glynn, Zaphiropoulos, Pressman & Unden, 1996; Raffel, 
2004) can cause activating mutations of Smo, which subsequently results in gene 
disrupted Gli1 and Gli2 transcription (Xie, Murone, Luoh, Ryan, Gu, & Zhang, 
1998).  
 
The connections between the Hh pathway and cancer was first identified by the 
observation that mutations in the Ptch1 receptor were associated with the rare 
condition known as Gorlin’s syndrome (Johnson, Rothman, Xie, Goorich, Bare, & 
Bonifas, 1996). Patients with this condition develop sporadic basal cell carcinomas 
(BCCs) and are also at an increased risk of developing medullablastoma, a tumour of 
the progenitor cells of the cerebellum. This link was further developed when a 
majority of BCCs were observed with deletion and insertion mutations in the Ptch1 
receptor protein; these mutations produce truncated proteins together with the loss of 
heterozygosity (LOH) which inhibits the ability of Ptch to supress Smo resulting in 
dysregulated Hh signalling (Xie et al., 1998). In addition, Gli1 protein 
overexpression has also been noted in BCC like tumours in mice, establishing the 
importance of Gli transcription in this tumorigenic process (Nilsson, unden, Krause, 
Malmqwist, Raza & Zaphiropoulos, 2000).  
 
Furthermore, many tumours exhibit autocrine, Hh ligand dependent, uncontrolled 
pathway activation; examples of these types of tumours include, stomach, lung, 
pancreas, prostate, brain, liver and breast (Kinzler, Bigner, Bigner, Trent, Law & 
O’Brien, 1987; Yauch, Gould, Scales, Tang, Tian, & Ahn, 2008). Most of these 
tumours demonstrate elevated Hh ligand or ectopic Ptch and Gli expression. A recent 
study conducted by Yauch et al. (2008) highlighted that tumorigenesis by Hh 
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signalling can occur through paracrine mechanisms. The epithelial tumours secret Hh 
ligands into the tumour stroma, and this directly stimulates proliferation of the 
mesenchymal cells. In another study, conducted by Fan and colleagues (2004) they 
showed that prostate cancer signals to the stroma; this was evident through Hh-
induced elevated Ptch and Gli expressions in murine stroma.  
 
Aberrant activation of Hh signalling has also been reported in human small cell lung 
cancer (SCLC) cell lines (Watkins et al., 2003). Activation of the Hh signalling 
molecule Smo promoted the clonogenicity of human SCLC in vitro and subsequently 
initiate and progress mouse SCLC in vivo (Park, Martelotto, Peifer, Sos, Karnezis, & 
Mahjoub, 2011). Reciprocally, when Smo was deleted in mutant lung epithelial cells, 
the initiation and progression of SCLC in mice was greatly supressed. Additionally, 
following chemotherapy using pharmacological inhibitors of Hh signalling, these 
mice showed inhibited SCLC growth (Park et al., 2011). These roles of Hh signalling 
in SCLC demonstrate crucial functions in the development and maintenance of 
SCLC. Effects of Hh signalling blockage were also demonstrated by Berman et al. 
(2003), where cyclopamine (a compound that interferes with Smo activity preventing 
Hh induced Gli expression)  treatment in murine medulloblastoma cells blocked cell 
proliferation and also induced changes in gene expression, thus establishing a 
specific role for Hh signalling in medullolastoma growth.  
 
The Gli transcription factors also regulate several cellular functions in malignant 
transformation such as cell cycle progression and apoptosis (Dennler, Andre, 
Alexaki, Li, Magnaldo, & Dijke, 2007). High levels of Gli1 expression have been 
noted in human Glioblastoma (Kinzler et al., 1987), and these high levels of Gli1 
were also expressed in other varieties of glial tumours, with Gli1 overexpression 
leading to hyper-proliferation of the central nervous system (Dahmane, Sanchez, 
Gitton, Palma, Sun, & Beyna, 2001). Overexpression of Gli1 has also been identified 
in a variety of brain tumours ranging from low-grade to high-grade. This was evident 
in a study that identified overexpression of the Hh mediator Gli1 (Clement, Sanchez, 
Tribulet, Radovanovic & Altaba, 2007). Furthermore, inhibiting Gli1 expression 
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using small interfering RNA, affected cell proliferation in primary cultures of these 
tumour cells (Clement et al., 2007). 
 
Recent evidence now indicates that deregulated tumour formation not only promotes 
tumour formation but is also required for tumour maintenance. This is evident in 
transformed cells that continue to require Hh activity for growth and survival. This 
was shown in a study conducted by Thayer et al. (2003) where all of the 26 
pancreatic adenocarcinoma cell lines expressed Hh target genes. Furthermore, 
treatment of tumour cells with cyclopamine induced apoptosis and loss of 
proliferation in more than half of these cell lines. In support, a previous study 
conducted by Dahmane et al. (2001) a subset of Glioma cell lines responded to 
cyclopamine-mediated inhibition of Hh signalling. Similarly, other digestive tract 
derived tumours such as stomach and oesophagus showed increased levels of Hh 
pathway signalling, and as expected these cell lines were also susceptible to 
cyclopamine-mediated inhibition of tumour growth (Berman et al., 2003).  
 
It is believed that tumour growth might depend on some cancer stem cells (CSCs) 
which are similar to normal stem cells, and regulate the same signalling molecules as 
normal stem cells. Increasing evidence supports the concept that abnormal formation 
and growth of cancer is due to deregulated signalling pathways in stem cells 
including the Hh pathway (Rubin & De Sauvage, 2006). Studies have shown that Hh 
signalling regulates self-renewal of CSC in breast, glioma and multiple myeloma 
(Clement et al., 2007). Self-renewal is required for the maintenance of malignant 
clones as reported in mouse models of chronic myeloid leukaemia (CML) which 
provides evidence that Hh signalling regulates this self-renewal property (Peacock et 
al., 2007). In this study, genetic disruption of Smo activity leading to loss of Hh 
signalling, lead to the inhibition of BCR-ABL (tyrosine-kinase inhibitor, first line 
therapy for patients with chronic leukaemia) expressing leukaemia stem cells and 
prolonged survival (Peacock et al., 2007). Active Hh signalling has also been 
identified in Glioblastoma CSCs, where the use of pathway inhibitors such as 
cyclopamine or siRNA (small interfering RNA) specifically targeting pathway 
components resulted in loss of tumorigenesis (Clement et al., 2007). Similarly, in 
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breast cancer, stimulating the activation of Hh pathways in CSCs using the Hh ligand 
and Gli1 or Gli2, or on the other hand inhibiting Gli1 or Gli2 expression using 
specific siRNA, altered the expression of BMI-1, which is a self –renewal regulator 
in normal stem cells (Liu et al., 2006). 
 
CSCs have also been implicated in tumour progression and metastases development 
in solid tumours, and again Hh signalling has been reported to be playing a critical 
role in these processes (Mani, Guo, & Liao, 2008). For example, in colon carcinomas 
derived from primary clinical specimens, the Hh activity within the CSCs was 
evident by high expressions of Gli1, Gli2 and Ptch in their cellular compartments 
(Mani et al., 2008). Moreover, inhibiting Hh pathway activity in these cells with 
cyclopamine or siRNA to Gli1, Gli2, and Smo, reduced tumour cell proliferation and 
induced apoptosis (Mani et al., 2008). Furthermore, using short hairpin RNA 
(shRNA) against Smo eliminated metastatic development in these tumours. Tumours 
contain only small amount of CSC are typically resistant to chemotherapy and 
radiation because they are slow growing cells (Beachy, Karhadkar & Berman, 2004).  
The fact that Hh signalling has been identified in several types of CSCs would mean 
that inhibiting Hh signalling is a promising therapeutic target to deplete tumour 
forming CSCs.   
 
It is certain that different components of the Hh pathway play pivotal roles in the 
biology of different cancers, and amongst these the Gli transcription factor especially 
Gli2, plays a predominant role. Kim et al. (2007) demonstrated that selective down-
regulation of Gli2 inhibited proliferation of hepatocellular carcinoma cells (HCC), 
inhibited expression levels of cell survival markers such as Bcl-2 and c-Myc, and 
enhanced expression levels of cell cycle inhibitor marker p27. Subsequent studies 
following this showed that high expression of Gli2 in HCC tissues is associated with 
poor prognosis in patients (Zhang et al., 2013). 
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1.5.5 Hedgehog pathway and MM 
Similar to other cancers, development of MM is considered to be a multi-step 
process that reveals mutations in different genes. These genes are commonly 
involved in growth and are regulated by pathways including the Hh signalling 
pathway (Greillier & Astoul, 2008). The aberrant expression and inappropriate 
activation of the Hh pathway has induced many cancers including non-small cell 
lung cancer and Medulloblastoma (Dennler et al., 2007). However, the significance 
of aberrant Hh pathway signalling in the development and growth of MM still 
remains to be determined.  
 
A recent study conducted by Shi et al. (2012) was the first to document a role for Hh 
signalling in MM cell growth. They observed an increased expression of Ptch1, Gli1, 
Shh and Hhip in frozen tumour  tissues from 39 MPM patients suggesting activation 
of the Hh pathway. They observed that  high Gli1 expression levels were associated 
with poor patient survival. They then expanded their investigation to examine the 
activity of the Hh signalling pathway in MPM tumours, and the effects of inhibiting 
this pathway in primary mesothelioma cell cultures and in a mouse xenograft model. 
Activation of the pathway was also demonstrated in MM cells, as blocking Hh 
signalling with cyclopamine resulted in a downregulation of Gli1 expression in more 
than half the cell lines examined.  
  
In vivo analysis using MPM xenografts (transplantation of cells from one species to 
another) determined that expression of Dhh correlated with human Gli1 and Ptch1 
expressions, which suggests autocrine Hh activity in some MPM. Treatment of two 
primary MPM cultures obtained from xenografts in mice with Hh antagonist resulted 
in a dose dependent decrease of cell survival, indicating the role of Hh signalling in 
MPM growth. They also showed that inhibitors targeting Smo could decrease Gli 
expression and cell growth and subsequently, decreased cell proliferation in cell 
cultures. In conclusion, this study identified an upregulation of Hh signalling in 
MPM tumours. Additionally, observing that Smo inhibitors decreased cells growth 
both in vitro and in vivo. 
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Li et al. (2013) in a current study reported an essential role for Gli transcription 
factors in MPM tumour growth. They showed that a majority of MPM tumour tissues 
had significant higher levels of Gli1, Gli2 and their downstream target genes, and by 
inhibiting Gli1 and Gli2 using specific siRNAs, supressed MPM cell proliferation in 
vitro and in vivo, thus highlighting Gli1 and Gli2 as important and potent therapeutic 
targets in MPM. 
 
Hh signalling is unlikely to be a sole effector pathway in tumorigenesis and there is 
growing evidence to suggest that it works with several other oncogenic factors for 
tumour formation, including growth factors such as TGF-β. Similar to the Hh 
members, TGF-β has emerged as an important molecule to be involved in various 
physiological processes and under appropriate conditions contributes to the 
aggressiveness and neoplastic progression in a variety of tumour types. 
 
 
1.6 TGF-β  
TGF-β is a multifunctional peptide that was first identified for its ability to cause 
phenotypic transformation of rat fibroblasts (Sporn, Robers, Wakefield & Assoian, 
1986). TGF-β has subsequently been shown to have various regulatory actions in a 
variety of normal and neoplastic cells, by regulating several functions including 
growth, differentiation, proliferation, adhesion and apoptosis (Sporn et al., 1986). 
TGF-β’s are important regulators of diverse developmental processes and 
homeostasis, and disruption of their activity has been implicated in a variety of 
human diseases including cancer (Sporn et al., 1986). More than 30 proteins have 
been identified as members of the TGF-β superfamily, including activins and bone 
morphogenic proteins (BMP) (Sporn et al., 1986). There are three mammalian TGF-
β isoforms, TGF-β1, TGF-β2 and TGF-β3 and are synthesised by a wide variety of 
cell types including platelets, macrophages, fibroblasts and tumour cells (Savage, 
Das, Finelli, Townend, Sun, Baird & Padgett, 1996). 
 
TGF-β was initially discovered in normal rat kidney fibroblasts, where TGF-β was 
measured for its ability to stimulate proliferation, and could also transform rat kidney 
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fibroblasts (Sporn et al., 1986). However, other contradicting studies also showed 
that TGF-β was essentially identical to a previously identified growth inhibitor, 
which was characterised in monkey kidney cells and which inhibited cell 
proliferation through autocrine mechanisms (Savage, Das, Finelli, Townend, Sun, 
Baird & Padgett, 1996). In support, Moses et al., 1987 showed that TGF-β is 
involved in the mitogenic process of fibroblasts, where it inhibits epithelial and 
endothelial cell proliferation in vitro. Other regulatory functions of TGF-β include 
initiating a cascade of events leading to neovascularization and matrix synthesis 
(Latterio, Geiser, Kulkarni, Roche, Sporn & Roberts, 1994), transport of glucose and 
amino acids, and glycolysis in fibroblasts, with a more specific action of enhancing 
fibronectin and collagen production in these cells (Smith et al., 1999). Thus the 
application of TGF-β to connective tissues, leads to fibrosis and angiogenesis (Sporn 
et al., 1986), suggesting that it may have application in tissue repair caused by 
trauma.  
 
 
1.6.1 Regulation of TGF-β 
TGF-β is synthesized as a large precursor protein which is then cleaved to generate 
mature the ligand (Mehra & Wrana, 2002). This pre-protein is about 100kDa in size 
and consist of an amino terminal and a mature carboxyl terminal (Gentry, Lioubin, 
Purchio & Marquardt, 1988). Cleavage is mediated by furins-which are pro-proteins 
that process latent TGF-β into biologically active forms (Matthews, Goodman, 
Gorman & Wells, 1994). The cleavage pro-region for TGF-β, also known as latency 
associated peptide (LAP), remains non-covalently bonded to the mature peptide to 
form a latent TGF-β complex. Thereafter, the latent TGF-β complex is secreted and 
undergoes further processes in the extracellular matrix (Thomsen & Melton, 1993). 
Various different cells synthesize TGF-β and essentially all have high affinity 
receptors for this peptide (Sporn et al., 1986).  
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1.6.2 TGF-β receptors 
The TGF-β ligand binds to several specific cell membrane receptors. These 
membranes are of high affinity and are founds in essentially all normal and 
malignant, epithelial and mesenchymal cells (Clark & Coker, 1998). These 
transmembrane surface receptors carry TGF-β signal into the cell. Massague and 
colleagues 1998, characterised TGF-β receptors, whereby radioactively labelled 
TGF-β was cross linked with cell surface proteins which revealed that TGF-β binds 
to three types of receptors and were named as type I, II, and III receptors.  
 
Type I and II receptors are glycoproteins of 55 kDa and 70 kDa respectively, with a 
core polypeptide of around 500-570 amino acids (Massague, 1998). The receptors 
have a relatively short extracellular region (approximately 150 aminoacids), N-
glycosylated, and around ten or more cystines which determine the general fold in 
that region, and three of these cystines form a cluster near the transmembrane 
sequence (Ebner, Chen, Shum, Lawler & Zoncheck, 1993). Lin and colleagues 
(1992), identified type II receptor with preferentially bound activin and TGF-β1 
through expression cloning. The type I receptor has received many names. It is 
generally referred to as activin receptor like kinase (ALK) (Clark & Coker, 1998) or 
TβRI. Whereas type II receptor subfamily that specifically binds to TGF-β is known 
as TβRII (Wrighton, Lin & Feng, 2009). In contrast to type I and type II receptors, 
type III plays an ancillary role, whereby they modulate their activity by regulating 
ligand access to type I and type II. 
 
The receptors comprise of an intracellular kinase domain which phosphorylates 
serine and threonine residues (Ebner et al., 1993). Signalling is initiated when the 
TGF-β ligand binds to the type II receptor, that interacts with a specific type I 
receptor (ALK5/TβRI) forming the mature signalling complex (Moustakas, Lin, 
Henis, Plamondon, O’Connor-McCourt & Lodish, 1993) Figure 1.4. This formation 
of ligand induced receptor complex leads to the phosphorylation of the type I 
receptor which activates the SMAD proteins that carry the signal to the nucleus and 
initiate transcription of the target genes (Ebner et al., 1993). 
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Figure 1.4: Interaction of TGF-β ligand with its type I and type II receptors. The 
phosphorylation step induces transduction pathway (reproduced from Attison & 
Wrana, 2002). 
 
 
1.6.3 SMAD signalling pathway 
After type I and II receptor activation, TGF-β signalling is mediated by the SMAD 
signalling pathway (Padgett, 1999). The SMAD proteins were named after the 
homologous proteins referred to as the Mad gene in Drosophila and the sma gene 
from C. elegans (Derynyck, Gelbart, Harland, Heldin, Kern & Massague, 1996). The 
first experimental evidence that SMADs functions downstream of receptors was 
performed through genetic mosaic analysis in C.elegans (Savage et al., 1996). 
Thereafter, eight different SMAD proteins were identified, divided into three 
functional categories: the receptor regulated SMADs (R-SMAD), common SMADs 
(co-SMAD) and inhibitory or antagonistic SMADs (I-SMAD). The intracellular 
proteins R-SMADs and co-SMADs are composed of three parts: the highly 
conserved Mad homology 1 and 2 (MH1 and MH2), N-terminal and a C-terminal. 
The I-SMADs are similar, except they have poorly conserved MH1 domain 
(Massague, 1998). 
 
The R-SMADs (SMAD 1, 2, 3, 5 and 8) are phosphorylated by the type I receptors. 
The phosphorylation of the R-SMADS forms a complex with the co-SMAD, of 
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which SMAD4 is the only member (Massogue, Blain & Lo, 2000). The co-SMAD 
works as a co-activator or a co-suppressor, thereby possibly regulating positive and 
negative gene expression. In contrast, the I-SMADs (SMAD 6 and 7), act as 
antagonizing SMADs counteracting the effects of R-SMADs Figure 1.5 (Massague, 
1998). These three SMAD groups represent the signalling pathway for TGF-β, which 
transmits signals from the receptors to the nucleus to regulate transcription activity of 
TGF-β target genes (Massogue et al. 2000). 
 
 
 
Figure 1.5: The SMAD family members from vertebrates indicating highly 
conserved MH1 and MH2 collaborates with co-SMADs. The antagonistic SMADs 
counteract that activation (reproduced from Massague, 1998). 
 
 
1.6.4 TGF-β Signal transduction through the SMAD pathway 
TGF-β1 is the most abundant and most expressed isoform (Elliot & Blobe, 2005). 
TGF-β is secreted into the extracellular matrix as a latent protein complex, which is 
then modified into a biologically active form (Padgett, 1999). A cellular response is 
achieved when the activated TGF-β binds to receptor specific TBRII and 
ALK5/TβRI, which in turn initiates phosphorylation of the intracellular receptor 
regulated SMADs, SMAD2 and SMAD3 (Elliot & Blobe, 2005). These 
phosphorylated SMADs heterodimerise with the co-SMAD, SMAD4 forming a 
complex, which then translocate to the nucleus (Elliot & Blobe, 2005). Accumulation 
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of this SMAD complex in the nucleus initiates transcription of the TGF-β target 
genes (Figure 1.6, Elliot & Blobe, 2005). SMADs 1, 6 and 8 are activated in 
response to bone morphogenic proteins (BMP) signals. 
 
 
Figure 1.6: the TGF-β SMAD signalling pathway showing binding of the TGF-β to 
their receptors and downstream SMAD signalling (reproduced from Elliot & Blobe, 
2005).  
 
Some studies suggest that TGF-β receptors can interact with a number of proteins, 
activating other signalling pathways. TGF-β induced signals are either transduced in 
SMAD-dependent (canonical) or SMAD-independent (non-canonical) pathways 
(Padgett, 1999; Massague, 1998).  
 
 
1.6.5 Non-canonical TGF-β signalling pathways 
Although TGFβRI & RII and SMADs comprise the TGF-β signalling pathway, other 
non SMAD pathways have been identified that signals through TGF-β, such as 
mitogen activated protein kinase (MAPK-JNK/ERK) (Engel, et al., 1999; Fink et al., 
2001), Rho guanosine triphosphatase and PI3 kinase/Akt (Figure 1.7, Bhowmick et 
al., 2001), Evidence of TGF-β activating the MAPK pathway came from cells 
overexpressing dominant negative SMAD4 and SMAD4-deficient cells. In these 
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cells, activation with JNK/MAPK was enough to elicit TGF-β regulated response 
(Engel et al., 1999). The precise molecular mechanisms by which TGF-β activates 
MAPK remains unclear however, evidence suggests that in epithelial cells activation 
of ERK is involved in TGF-β mediated Ras signalling (Bhowmick et al., 2001; 
Zhang, 2009). Similarly, TGF-β induced epithelial to mesenchymal transition (EMT) 
involves non-SMAD pathways, signalling via the PI3K/Akt pathway (Bhowmick et 
al., 2001). These multistep SMAD and non-SMAD pathways activated by TGF-β 
involves a complex mechanism. A greater understanding of this TGF-β mediated 
pathways in different cell types and in the context of specific environments might 
provide insights into TGF-β signalling in various cancers including MM. 
 
 
 
Figure 1.7: Representation of canonical and non-conical TGF-β signalling pathways 
(reproduced from Chaudhury & Rowe, 2009). 
 
 
1.6.6 Role of TGF-β in cancer 
TGF-β is an essential regulator of cellular and physiological processes, and 
alterations in the TGF-β signalling pathway and resistance to inhibition of 
proliferation is frequently observed in cancers. TGF-β function both as an anti-
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proliferative factor and as a tumour promoter, and various components of the TGF-β 
signal transduction pathway that normally act as tumour suppressors, are mutated in 
different cancers (Massogue et al., 2000). Functional loss of TGF-β and its 
association with tumorigenesis has been demonstrated in gastric and colon 
carcinomas with somatic mutations in the type II TGF-β receptor (Suzuki et al., 
2004).  Pancreatic, lung and breast are other cancers identified carrying mutations in 
the TGF-β signalling pathway components (Suzuki et al., 2004). Therefore, these 
diverse activities have promoted investigation to broaden the understanding of how 
TGF-β family members signal to evaluate diagnostic, prognostic and predictive 
markers for cancer patients. 
 
 
1.6.7 TGF-β signalling in MM 
There is strong evidence to support the involvement of TGF-β in MM growth. 
Firstly, significant levels of TGF-β are produced by most human (Fitzpatrick et al., 
1994; Shetty et al., 2009) and murine MM cell lines (Kuwahara et al., 2001). In 
addition MM patients have been documented with high levels of TGF-β, whereby 
immunoreactivity to TGF-β was observed in more than 90% MM patients (Jagirdar, 
Lee, Reibman, Gold, Aston & Begin, 1997). Maeda et al. (1994) measured TGF-β 
levels in pleural effusions from MM patients, which was approximately 280 pmol/L, 
nearly three times greater compared to pleural effusions from primary lung cancer 
patients and nearly six times higher compared to pleural effusions from non-small 
cell lung cancer (NSCLC) and breast cancer patients (Suzuki et al., 2004).  
 
Secondly, involvement of TGF-β in MM pathogenesis has been observed in several 
studies. Fitzpatrick et al. (1994) transfected mouse MM cells with antisense RNA to 
TGF-β1 and TGF-β2 and observed a delay in tumour growth when these transfected 
MM cells were adoptively transferred to recipient animals. These findings were 
supported by Marzo et al. (1997) who demonstrated that administration of TGF-β2 
antisense oligonucleotides in vivo reduced tumour growth in a MM animal model. 
Thirdly, there is evidence to suggest that TGF-β may potentially respond to 
immunological therapy. Suzuki et al. (2004) explored the effects of a soluble TGF-β 
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type II receptor (sTGF-βR) which specifically inhibits TGF-β1 and TGF-β3 isoforms 
(Smith et al., 1999) in AB12, AC29 and AB1 murine MM tumour models. AB12 and 
AC29 cells produce large amounts of endogenous TGF-β whereas AB1 did not 
(Christmas, Manning, Garlepp, Musk & Robinson, 1993).  sTGF-βR treatment 
inhibited AB12 and AC29 tumour growth in mice. In contrast, AB1 growth was not 
affected by sTGF-βR treatment. Thus blocking of TGF-β is a promising anticancer 
therapy to treat MM patients. 
 
In recent years there has been a strong focus on examination of signalling pathways 
in promoting tumour growth, which has lead to various anticancer treatments being 
developed. Most current therapies aim at blocking these signalling pathways. 
However, not all tumours are responsive to these inhibitors, and some tumours that 
may be responsive initially, become resistant during the course of the treatment. 
Therefore, there is need to develop a broader understanding of the regulation of 
signalling pathways in tumorigenesis process of various cancers to develop better 
therapeutic approaches. 
 
Researchers are now exploring the interaction or cross talk between different 
signalling pathways in tumour growth. Initially, studies examined the effect of 
interacting signalling pathways on cellular functions, particularly in embryonic 
developmental and physiological processes. Recently, studies have looked at 
pathway interactions and how they are regulated in tumorigenesis.  
 
 
1.7 TGF-β cross-talk with Wnt and Hippo signalling pathways 
An example of these interacting pathways is between the TGF-β and Wnt signalling 
pathways. Attisano and Labbe. (2004) demonstrated that TGF-β and Wnt ligands can 
co-orporate to regulate cell differentiation and control gene expression patterns, and 
described their co-orporation in promoting tumorogenesis in mice. 
 
Wnt proteins are secreted glycoproteins that are important in various developmental 
processes including the formation of body axis during early embryogenesis (Moon, 
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Bowerman, Boutros & Parriman, 2002). In addition to its developmental role, 
inappropriate activation of the Wnt pathway has been implicated in various cancers 
(Cadigan & Nusse, 1997). β-catenin is the key component of the Wnt signalling 
pathway. In the absence of the Wnt ligand, the pathways intermediate molecules 
such as APC (Adenomatous Polyposis Coli), axin and GSK3 (Glycogen Synthase 
Kinase 3) forms a complex that results in phosphorylation and degradation of β-
catenin, however, in the presence of Wnt ligand, this ligand binds to frizzled proteins 
which then stabilizes β-catenin, and accumulates in the nucleus associating itself 
with LEF1/LCF transcriptional factors to regulate target gene expression (Skromne 
& Stern, 2001). Mouse models have provided an insight into the cross-talk between 
TGF-β and Wnt signalling pathways, disrupted TGF-β signalling in the context of 
activated Wnt promoted tumorigenesis (Skromne & Stern, 2001). TGF-β signals 
through the SMAD pathway and Takaku and colleagues 1998, isolated SMAD4/APC 
heterozygotes and showed that these mice developed more severe form of malignant 
tumours from intestinal polps compared to mice with just the APC. In another study, 
SMAD4/APC heterozygote mice were challenged with carcinogens and these mice 
developed significant numbers of pancreatic acinar foci compared to the control APC 
mice (Cullingworth, Hooper, Harrison, Mason, Sirard, & Patek, 2002). 
 
Similarly, interactions between TGF-β and Hippo signalling pathways have been 
noted in some cancers, including MM, whereby mutations in the Hippo cascade were 
observed in MM cases which then negatively regulated its pathway mediators. The 
Hippo signalling pathway controls organ size in animals by regulating cell 
proliferation and apoptosis (Hall, Wang, & Miao, 2010). This pathway induces 
expression of several organ growth genes such as cyclin E.  Yes-associated proteins 
(YAP) human homolog is a key transcriptional target of the Hippo pathway (Hall et 
al., 2010). YAP plays a conserved role in the tumorigenic processes of various 
cancers. Fuji et al. (2012) observed a functional interaction between TGF-β and 
Hippo pathway in regulating connective tissue growth factor (CTGF). There was an 
induced CTGF expression in MM cells by the formation of YAP-TEAD4-SMAD3-
p300 complex on the CTGF promoter (Fuji et al., 2012). In support, xenografted 
mice showed a prolonged survival rate when the CTGF expression was knocked 
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down in MM cell, suggesting CTGF as an important modulator of MM growth and 
pathology, providing a novel therapeutic approach for MM (Fuji et al., 2012). 
 
Functional interaction between TGF-β and Hh signalling in cancers has also been 
identified by several investigators. TGF-β and Hh are involved in numerous 
overlapping processes during embryonic development and several studies have 
identified this interaction in cancers.  
 
 
1.8 Interaction between Hh and TGF-β signalling pathways 
As described earlier, the transcriptional response to Hh signalling is mediated by the 
Gli transcriptional factors. Gli regulates several cellular functions linked to malignant 
transformation, such as cell cycle progression, differentiation and apoptosis (Kasper, 
Frischauf & Abager, 2006). Also mentioned previously was the essential role of 
TGF-β essential in physiological processes including tissue repair, control of cell 
growth, differentiation and immune regulation. Subsequently, expression of TGF-β 
isoforms contributing to the severity and progression of neoplasms have also been 
identified in various tumour types (Derynck et al., 1996). Recent studies have shown 
that Gli is not solely regulated by Hh signalling but also by other pathways such as 
TGF-β. Studies have examined the capacity of TGF-β to affect the expression of Hh 
signalling molecule Gli1 and Gli2 in vitro and in vivo.  
 
Dennler et al. (2007) identified Gli2 as the most transcriptionally active of the Gli 
proteins and a target of TGF-β/SMAD signalling, independent of the Hh signalling 
pathway. The capacity of TGF-β to rapidly induce Gli2 expression in the presence of 
Hh inhibitor cyclopamine, revealed this pathway interaction. Interestingly, Gli1 is 
also induced by TGF-β but in a Gli2-dependent manner which was also independent 
of Hh signalling. In vitro studies confirmed Gli1 and Gli2 expressions induced by 
TGF-β in various cell types including breast carcinoma cells, human dermal 
fibroblasts, cutaneous melanoma, glioblastoma and keratinocytes. These findings 
were supported by in vivo studies, where transgenic mouse models overexpressing 
TGF-β1 activated Gli1 and Gli2 expression in a SMAD3 dependent manner. Finally 
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they showed TGF-β induced Gli1 and Gli2 expression was greatly inhibited 
inhibitors such as ALK5 inhibitors and transfected Gli2 siRNA oligonucleotides in 
cyclopamine resistant pancreatic adenocarcinoma cell lines (Dennler et al., 2007).  
 
Yoo, Kang, Kim and Oh. (2008) investigated the role of Shh and TGF-β signalling in 
the metastatic process of human gastric cancers by examining ALK5 and Gli 
immunohistochemical staining on tumour biopsies from gastric cancer patients. 
ALK5 and Gli expression was classified as strong in 2% and 48% of biopsies 
respectively, Figure 1.8. 
 
 
Figure 1.8: Gli immunohistochemical stain x 200, Gli highly expressed in an area of 
gastric tissue (light brown staining) (reproduced from Yoo et al., 2008) 
 
Several independent groups have confirmed induction of Gli, specifically Gli2 by 
TGF-β. Hu and colleagues, (2004) found that TGF-β signalling increased Gli2 
expression, which then influenced the progression from ductal carcinoma in situ to 
invasive carcinoma. These findings were consistent with the findings of Alaxaki et al 
(2010), who found that TGF-β increased Gli2 expression which subsequently 
increased its downstream target Gli1 and this influenced cell differentiation and 
progress of myoepithelial cell to invasion. Edson and colleagues, (2010) found that 
in normal granulosa cells, Gli2 is a TGF-β-regulated gene and suggested that Gli 
may contribute to cancer progression in the ovary. Furthermore, a recent study by 
Johnson et al. (2010) observed that blocking Gli signalling with a Gli2 repressor 
gene in metastatic breast cancer cells reduced TGF-β-induced parathyroid hormone 
mRNA expression, thereby reducing tumour-induced bone destruction. TGF-β is a 
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molecule shown to be important in MM, however the aberrant activation of Hh 
signalling and the interaction of its mediators with TGF-β remains to be determined.  
While TGF-β contributes to the biological effects of the Hh pathway and its 
mediators, it is also highly likely that the Hh pathway could induce TGF-β activity. 
This opposite action was evident in non-small cell lung cancer (NSCLC), where 
pharmacological inhibitors of the Hh pathway were shown to inhibit TGF-β-induced 
epithelial to mesenchymal transition (EMT) (Maitah, Ali, Ahmed, Gadgeel & Sarkar, 
2011). Hh and TGF-β signalling can form a vicious cycle where it can promote 
tumour growth and development in cancers. However the interaction between these 
pathways in MM is unknown. 
 
 
1.9 Scope of thesis 
Numerous studies have shown abnormal Hh signalling in various cancers. Similarly, 
TGF-β signalling aids to the pathogenesis in many cancers including MM. However, 
only a few studies have examined the interaction between the two pathways in cancer 
and there have been no published studies examining their interaction in MM. Current 
treatment regimens in MM are largely unsuccessful. Therefore, new innovative 
treatments such as molecular targeted approaches needs to be developed.  
 
Previous studies by our laboratory and others have shown the contribution of TGF-β 
in MM. Our laboratory is now investigating the importance of Hh signalling in these 
cells. Importantly, we now have preliminary data suggesting that TGF-β affects the 
downstream effector molecules of the Hh pathway in MM cells. Its important then to 
understand how the TGF-β and Hh pathways interact and what regulates these 
pathways may identify novel targets for therapeutic intervention.   
 
1.9.1 Research Direction 
1.9.1.1 General Hypothesis 
TGF-β induces Gli1 and Gli2 expression in MM cells through activation of the 
SMAD signalling pathway. 
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1.9.1.2 Aims 
Aim 1. To examine the effect of TGF-β1 and TGF-β2 on the expression of Gli1 and 
Gli2 in MM cells.  
(a) Determine the levels of endogenous TGF-β1 and TGF-β2 mRNA in MM 
and control cell lines. 
(b) Validate the activity of recombinant TGF-β1/2 by measuring pSMAD2 
proteins and human collagen type-1α1 mRNA expression in MM and control 
cells. 
(c) Examine the effect of TGF-β1 and TGF-β2 on Gli1 and Gli2 mRNA levels 
in MM and control cells. 
 
Aim 2. To determine if TGF-β-induced Gli mRNA is independent of the Hh 
signalling pathway and examine the effects of blocking TGF-β on Gli1 and Gli2 
mRNA levels. 
(a) Evaluate the effect of blocking ALK5 inhibitor (SB-431542) on TGF-
β1 and TGF-β2 mediated Gli1 and Gli2 mRNA levels. 
(b) Evaluate the effect of ALK5 inhibitor on SMAD2/3 protein 
expression 
(c) Examine the effect of TGF-β1 and TGF-β2 on Gli1 and Gli2 mRNA 
levels in the presence of a Smo inhibitor 
 
Aim 3. To determine the signalling pathway through which TGF-β regulates Gli1 
and Gli2 expression. 
(a) Effect of TGF-β stimulation on SMAD2/3 protein expression 
Determine if TGF-β-induced Gli mRNA is mediated through the SMAD2/3 
pathway.  
 
To address aim 1 a) I will measure mRNA expression of TGF-â1/2 in MM, control 
cells (MeT-5A) and primary mesothelial cells by real-time PCR. In aim 1 b) I will 
isolate RNA and protein from MM and MeT-5A cells after TGF-â1/2 stimulation and 
measure phosphorylation of SMAD2 proteins and human collagen type-1α1 mRNA 
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levels. In aim 1 c) I will isolate RNA from MM and MeT-5A cells after TGF-â1/2 
stimulation and measure Gli1/2 mRNA levels by real-time PCR.  
 
For aim 2 and 3, based on aim 1(c) I will choose 1 MM and MeT-5A cell line for 
subsequent studies. 
 
In aim 2 a) I will isolate RNA and protein from a 1 MM and MeT-5A cell lines after 
SB-431542 and TGF-β1/2 treatment. The expression of Gli1/2 mRNA levels will be 
measured by real-time PCR. In aim 2 b) the effectiveness of SB-431542 to inhibit 
TGF-β1/2 will be confirmed by SMAD2/3 protein expression by western blot 
analysis. For aim 2 c) cells will be pretreated with Hh pathway inhibitor 
cyclopamine, then stimulate with TGF-β1/2 and isolate RNA to measure Gli1/2 
mRNA levels by real-time PCR. 
 
For aim 3 a) the effectiveness of the siRNA to delete SMAD pathway will be 
confirmed by measuring SMAD2/3 mRNA and pSMAD2 protein by real-time PCR 
and western blot analysis respectively. Thereafter, I will isolate RNA and protein 
from a 1 MM and MeT-5A cell line that have been transfected with SMAD2/3 and 
control siRNA and treated with TGF-β1/2. The expression of Gli1/2 mRNA will be 
measured using real-time PCR. 
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Chapter 2 
Materials 
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2.1 Reagents 
2.1.1 Tissue culture 
Dulbecco’s modified eagle’s medium  GIBCO® Life Technologies™  
(DMEM)     Mulgrave, Victoria, Australia  
Foetal calf serum (FCS)   SAFC Bioscience  
Brooklyn, Victoria, Australia   
Gentamycin {10mg/ml}   GIBCO® Life Technologies™  
L-glutamine (L-Glut) {200mM}  GIBCO® Life Technologies™ 
Penicillin {10 000 units (U)/mL}  GIBCO® Life Technologies™  
/Streptomycin {10 000 µg/mL} (P/S) 
Trypsin-EDTA {0.25%}   GIBCO® Life Technologies™ 
 
2.1.2 Reverse transcription (RT-PCR) 
Omniscript reverse transcription kit  Qiagen® Chadstone, Victoria, Australia 
Deoxyribonucleoside triphosphates   Qiagen® 
(dNTPs) {5mM}     
Omniscript reverse transcriptase {4U/µl} Qiagen®  
Reverse transcriptase buffer {10x}  Qiagen®   
RNase inhibitor {4U/µl}   Qiagen®   
Random hexamers {3 µg/µL}  Life Technologies™   
  
2.1.3 Real-Time Polymerase Chain Reaction (PCR) 
Quantifast™ Probe PCR Master Mix {2x} Qiagen®   
Taqman® Universal PCR Master Mix Life Technologies™  
 
2.1.4 RNA Isolation 
Purelink™ RNA Mini Kit   Life Technologies™   
RNeasy Mini Kit    Qiagen®   
RNase Free DNase Set   Qiagen®     
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2.1.5 Protein Isolations 
Aprotonin     Sigma-Aldrich®  
Castle Hill, NSW, Australia   
β-glycerophosphate    Sigma-Aldrich®   
Dithiothreitol     Sigma-Aldrich®   
EDTA      Life Technologies™                               
HEPES     Sigma-Aldrich®   
Leupeptin     Sigma-Aldrich®   
Magnesium Chloride (MgCl₂)  Life Technologies™   
Nonyl phenoxypolyethoxylethanol (NP40) Sigma-Aldrich®   
Phenylmethanesulfonylfluoride (PMSF) Sigma-Aldrich®   
Sodium fluoride (NaF)   Sigma-Aldrich®    
Sodium molybdite dehydrate (NaMolyb) Sigma-Aldrich®    
Sodium orthovanadate (Na₃VO₄)  Sigma-Aldrich®    
Sodium pyrophosphate decahydrate (NaPyr) Sigma-Aldrich®    
Triton®X-100     Sigma-Aldrich®     
 
2.1.6 Western blot 
Acrylamide     BIO-RAD Gladsville, NSW, Australia 
Ammonium per sulfate (APS)  BIO-RAD  
Bromophynol blue    Sigma-Aldrich®   
Coomassie Plus™ Protein Assay Kit  Thermo Scientific  
Scoreby, Vic, Australia   
Immobilon western HRP substrate  Millipore Klisiyth, Victoria, Australia 
Instant Skim milk powder   Diploma Instant 
Balcatta, WA, Australia   
Nitrocellulose membrane   Whatman® Dassel, Germany   
Precision plus protein™    BIO-RAD    
dual colour standard  
Sodium dodecyl sulphate (SDS)  Sigma-Aldrich®    
Tetramethylethylenediamine (TEMED) Sigma-Aldrich®    
Polyvinylidene fluoride (PVDF)   Millipore  
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membrane     
Tween-20®     Sigma-Aldrich®     
 
2.1.7 Alphascreen® Surefire® Assay 
GAPDH Surefire® Assay kit   Perkin Elmer Life Sciences®  
Massachusetts, U.S.A  
Histone Surefire® Assay kit   Perkin Elmer Life Sciences®  
pSMAD2 Surefire® Assay kit  Perkin Elmer Life Sciences®   
Protein A acceptor beads   Perkin Elmer Life Sciences®   
Streptavidin coated donor beads  Perkin Elmer Life Sciences® 
 
2.1.8 Other reagents 
Absolute ethanol    Thermo Fisher Malaga, WA, Australia 
β- Mercaptoethanol    Sigma-Aldrich®    
Bovine serum albumin   Sigma-Aldrich® 
Dimethyl sulfoxide (DMSO)   Sigma-Aldirch®    
Double deionised H₂O   Sigma-Aldrich®    
Glycerol     Sigma-Aldrich®    
Glycine     Sigma-Aldrich®   
Lipofectamine™ 2000   Life Technologies™ 
Methanol     Chem Supply Gillman, SA, Australia  
Sodium chloride (NaCl)   Sigma-Aldrich®  
Tris-base      Sigma-Aldrich®    
        
2.1.9 Antibodies 
Anti-α-tubulin monoclonal primary   Sigma-Aldrich®     
antibody produced in mouse 
Secondary polyclonal anti-rabbit   Dakocytomation  
immunoglobulins/HRP    Campbellfield, Vic, Australia 
Secondary polyclonal anti-mouse   Dakocytomation  
immunoglobulins/HRP 
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pSMAD2 primary antibody   Cell Signalling Technology  
produced in rabbit     Boston U.S.A  
Total SMAD2/3 primary antibody  Cell Signalling Technology 
produced in rabbit  
  
2.1.10 Taqman® Primers/probes 
Phosphoglycerate kinase 1    Life Technologies™   
(PGK1) primer probe, VIC labelled 
Gli1 primer probe,    Life Technologies™   
FAM labelled. ID#: Hs01110766_m1 
Gli2 primer probe,    Life Technologies™   
FAM labelled. ID#: Hs01119974_m1 
TGF-β1 primer probe,    Life Technologies™   
FAM labelled. ID#: Hs00998129_m1 
TGF-β2 primer probe,    Life Technologies™   
FAM labelled. ID#: Hs00234244_m1 
SMAD2 primer probe,   Life Technologies™   
FAM labelled 
SMAD3 primer probe,   Life Technologies™  
FAM labelled 
Ptch1 primer probe,    Life Technologies™   
FAM labelled. ID#: Hs00970976_m1 
 
2.1.11 Inhibitors/Small Interfering RNA (siRNA) 
SB 431542, ALK5 inhibitor   Life Technologies™    
SMAD2 siRNA    Life Technologies™    
SMAD3 siRNA    Life Technologies™     
Control siRNA    Life Technologies™    
Control siRNA (FITC Conjugate)  Life Technologies™    
  
2.1.12 Instruments and equipment 
AGFA CP1000 X-ray processor  AGFA healthcare  
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Scoresby, Victoria, Australia 
Alphascreen proxiplate™ 384 plus  Perkin Elmer Life Sciences®  
Black top seal adhesive films   Perkin Elmer Life Sciences®   
CL-Xposure™ Film (18cm x 24cm)  Thermo Scientific  
Corbett research Thermal Cycler  Fisher Biotec Wembley, WA, Australia 
EnSpire® Multicode Plate Reader  Perkin Elmer Life Sciences®   
Hypercassette™    Amersham Bioscience Australia 
MicroAmp®  Fast Optical    Life Technologies™  
96 well plate {0.1 mL}  
MicroAmp® Optical Adhesive Film  Life Technologies™    
Moticam 3 CMOS Microscopy Camera Perth Scientific Malaga, WA, Australia 
Mr Frosty freezing container   Thermo Scientific  
NanoDrop 2000 spectrophotometer  Thermo Scientific     
Nikon® Coolpix 4500 camera  Nikon® Japan    
Nikon® Eclipse Ti-S inverted microscope Nikon® Kilda, Victoria, Australia  
Olympus® 1x - 81® Inverted   Olympus® Morley, WA, Australia 
Fluorescence microscope   
StepOne Plus™ Real-time PCR system Life Technologies™  
Wallac Victor²V™ multilabel counter Perkin Elmer Life Sciences®  
Western blot electrophoresis    BIO-RAD  
and transfer tanks  
 
2.2 Buffers/Reagent Recipes 
2.2.1 Glycine stripping buffer 
Glycine   50 mM 
SDS    35 mM 
Tween-20®   1% 
The components were dissolved in 1L ddH2O, the pH adjusted to 2.5 and stored at 
4ºC. 
 
2.2.2 Phosphate Buffered Saline (PBS) {20x} 
Na₂HPO4   0.2 M 
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NaCl    3 M 
KH₂PO4   30 mM 
KCl    55 mM 
The components were dissolved in ddH₂O, adjusted to pH 7.4 and made up to a final 
volume of 1 L, sterilised and stored at room temperature. The solution was diluted 
1:20 to 1x PBS in ddH₂O before use. 
 
2.2.3 Sample Loading Buffer {4x} 
Glycerol   40% 
Tris/HCl pH 6.8  0.25 M 
SDS    0.3 M 
Bromophenol Blue  0.04% 
β-mercaptoethanol  5% 
The components were dissolved in 20 mL ddH₂O, aliquoted into eppendorf tubes 
and froze at -20ºC until required. 
 
2.2.4 SDS-PAGE Running Buffer {10x} 
Tris-Base   0.25 M 
Glycine   2 M 
SDS    35 mM 
Components were dissolved content in 1 L ddH₂O, the pH checked to be around 8.0, 
and then stored at room temperature before being diluted 1:10 in ddH₂O before use. 
 
2.2.5 Stress Lysis Buffer (SLB) 
HEPES   20 mM 
MgCl₂    55 mM 
EDTA    0.02 mM 
β-glycerophosphate  30 mM 
NaCl    0.1 M 
Dilution was made up to a final volume of 500 mL in ddH₂O, adjusted to pH 7.7, 
Aliquoted in 5mL sterile tubes and froze at -20ºC until required for use. 
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2.2.6 SLB++ 
Triton®X-100   0.5% 
NP40    1% 
NaPyr    0.5 mM 
Na₃VO4   0.2 mM 
NaMolyb   1.0 mM 
NaF    1.25 mM 
Aprotinin   1 mM 
Leupeptin   1 mM 
PMSF    5 mM 
DTT    5 mM 
The components were added to 2 mL of SLB and used immediately. 
 
2.2.7 Tris Buffered Saline (TBS) {10x} 
Trizma Base   0.1 M 
NaCl    1.5 M 
The components were dissolved in 1 L ddH₂O, adjusted pH to 7.4 and stored at room 
temperature. The solution was diluted 1:10 with ddH₂O before use. 
 
2.2.8 TBS/Tween-20® (TBST) {1x} 
Tween-20®   1% 
1x TBS   1 L 
Tween-20® was dissolved in 1 L 1x TBS and thoroughly mixed then used 
immediately. 
 
2.2.9 Transfer Buffer {10x} 
Tris-Base            0.25 M 
Glycine            2 M 
SDS             3.5 M 
Components were dissolved in 1 L ddH₂O, the pH checked to see it was in the range 
of 8.0-8.3, stored at 4ºC and then diluted 1:10 in ddH₂O before use. 
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2.2.10 Tris/HCL at pH 6.8/8.8 
Tris/HCL           1.5 M 
The powder was dissolved in ddH₂O, pH adjusted to either to 6.8 or 8.8 and then 
made up to 50mL in ddH₂O before being stored at room temperature until required. 
 
2.2.11 5% Milk + TBST 
5% w/v Skim Milk Powder 
1x TBS + 1% Tween 20® 
Milk powder was dissolved in 1x TBST-T solution and used immediately. 
 
2.2.12 10% w/v Ammonium Per sulphate (APS) 
APS         1g 
APS was dissolved APS in 10mL ddH₂O, aliquoted in 1.5mL eppendorf tubes and 
stored at -20ºC until use. 
 
2.2.13 Western Blot Gels 
       Stacking Gel  Running Gel 
Acrylamide/Biscarylamide   6%   10% 
SDS {20%}     0.5%   0.5% 
Tris/HCl {1M}   0.125 M at pH 6.8 0.375 M at pH 8.8 
APS      75 µL   75 µL 
TEMED     10 µL   10 µL 
The components of 6% stacking gel and 10% running gel were mixed in separate 
falcon tubes and made up to 10 mL in ddH₂O. 
 
2.3 Other Solutions 
2.3.1 DNase 1  
Qiagen® RNase free DNase set contains DNase 1 in a powder form, which was 
diluted according to manufacturer’s directions in 550 µL of RNase free water. 
Aliquoted in 0.6 mL eppendorf tubes and stored at -20ºC until use. A 10 µL solution 
of DNase 1 was added to 70 µL of RDD buffer provided in the kit and used 
immediately.  
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3.1 Tissue Culture 
3.1.1 Cell lines 
Human mesothelioma cell lines used in this study were isolated from pleural 
effusions (CRL2081, JU77, LO68, NO36 and VGE) (Manning, Whiteker, Murch, 
Garlepp, Davis & Musk, 1991) or obtained from Plural Diseases Unit at Lung 
Institute of Western Australia. An SV40 transformed non-tumorigenic normal human 
mesothelial cell line (MeT-5A) originating from the pleural effusion of a non-
cancerous donor was also used (Ke at al., 1989). Primary mesothelial cells used in 
this study were isolated and cultured by Ms. Kimberly Birnie. These cells originated 
from pericardial fluids of patients undergoing heart surgery. Ethics approval for 
collection of these cells was provided by the Sir Charles Gardner Hospital Human 
Ethics Committee and RNA was isolated from these cells using the Qiagen® Reasy 
Mini Kit (section 3.6.1). 
 
3.1.2 Cell Culture conditions 
All cells were cultured in 75 cm² tissue culture flasks containing growth medium 
consisting of Dulbecco’s modified eagle’s medium (DMEM) with 10% foetal calf 
serum (FCS), 4 mM L-glutamine, and either 100 U/mL penicillin and 100 µg/mL 
Streptomycin or 5 mg/mL gentamycin. Cell cultures were switched to gentamycin in 
the middle of the study due to issues with bacterial contamination. Cells were 
incubated in 5% (v/v) CO₂ at 37ºC and passaged when confluent. 
 
3.1.3 Cell Thawing and Freezing 
Cell stocks were stored in liquid nitrogen (LN₂) and when required for culture, an 
aliquot was removed and thawed at 37ºC in a water bath. Cells were then added to a 
25 cm² flask containing 4 mL of growth medium. The next day the medium was 
changed to 5 mL growth medium. Once the cells were confluent, they were passaged 
and transferred to a 75 cm² flask.  
 
For cell freezing, 1 x 10
6
 cells were resuspended in 1 mL of freezing medium 
(DMEM with 50% FCS and 10% DMSO). The cell suspension was added to a 
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cryogenic vial and stored at -80ºC overnight in a Mr Frosty container. The following 
day, the vial was transferred to LN₂. 
 
3.1.4 Cell passage 
Once the cells were confluent, the medium was aspirated from the flask and the cells 
were washed twice with sterile 1x PBS to remove any remaining medium. 
Thereafter, 1 mL of 0.25% trypsin/EDTA was added. Once the cells detached from 
the surface of the flask, 1 mL of growth medium was added to neutralise the trypsin. 
A single cell suspension was formed by adding 9 mL of growth medium to the flask 
and pipetted up and down. Cells were then transferred to a sterile 15 mL falcon tube 
and centrifuged at 1200 rpm for 5 min at room temperature. The supernatant was 
aspirated and cells resuspended in fresh growth medium at appropriate 
concentrations. Cell lines CRL2081, JU77 and LO68 were split at a ratio of 1:10, 
NO36, VGE and MeT-5A were split at a ratio of 1:5. These cells were then made up 
to 10 mL growth medium in a new 75 cm² flask. 
 
3.1.5 Mycoplasma Testing 
Cell cultures were assessed for Mycoplasma spp. infection every time a cell line was 
removed from liquid Nitrogen (LN2). Mycoplasma are a group of micro-organisms 
that may cause changes in cells by altering their cell metabolism, morphology, as 
well as protein and RNA/DNA synthesis (Drexler & Uphoff, 2003). Following 
trypsinisation and cell resuspension in growth medium during cell passaging, 1mL of 
the cell suspension was added to a 1.5 mL microcentrifuge tube and centrifuged at 
400 x g for 5 min. The supernatant was aspirated and 1mL of 0.9% saline (NaCl) was 
added to the pellet and centrifuged at 400 x g for 5 min. The saline wash was 
repeated twice. The pellet was left in the tube and sent to PathWest Laboratory 
Medicine WA for mycoplasma testing. All the cell cultures used in this study were 
negative for Mycoplasma spp. 
 
3.1.6 Cell counting and seeding 
Cells were counted in a haemocytometer to determine the number of cells available 
for seeding. Following tryptinization and centrifugation, the cell pellet was re-
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suspended in 5 mL of fresh growth medium and a 10 µL aliquot of the cell 
suspension was added to 10 µL of trypan blue and 10 µL loaded into a 
haemocytometer. The cell concentration was calculated using the following equation: 
   
Number of cells per mL = Total number of cells x 10
4 
        4 
 
Based on this cell calculation, the correct concentration of cells were seeded into 
assay plates. Cells were plated in growth medium to a total volume of 3 mL in 6 well 
plates and 1 mL each in 12 well plates. Cells were then incubated in 5% (v/v) CO₂ at 
37ºC. The number of cells plated in each type of plate type for different experiments 
is shown in table 3.1. 
 
Table 3.1: Cell densities seeded for each experiment and the type of culture 
plate used. 
Cell line Experiment Cell density Type of plate 
LO68, CRL2081, 
JU77 
Basal gene 
expression 
0.75 x 10
5
 12 well 
NO36 Basal gene 
expression 
1.0 x 10
5
 12 well 
MeT-5A, VGE Basal gene 
expression 
1.5 x 10
5
 12 well 
LO68, CRL2081, 
JU77, MeT-5A 
Gene expression 
with stimulation 
2.5 x 10
5
 12 well 
LO68, MeT-5A Protein expression 
with stimulation 
5.0 x 10
5
 6 well 
Met-5A, CRL 
2081 
Gene expression 
with transfection 
1.0 x 10
5
 12 well 
MeT-5A, CRL 
2081 
Protein expression 
with transfection 
5.0 x 10
5
 6 well 
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3.2 Basal gene expression 
Following cell passage, cells were seeded in 12 well plates in triplicates at the 
optimal seeding density for different cell lines as outlined in table 3.1.  The correct 
number of cells made up to 1mL per well in full growth medium were seeded in 12 
well plates and incubated for 48 hr at 37ºC in 5% v/v CO₂. Following 48 hr 
incubation, cells were harvested and mRNA levels for TGF-β1 and 2 and Gli1 and 2 
determined according to section 3.6.  
 
3.3 TGF-β stimulation 
Following cell passage, cells were seeded in appropriate plates for mRNA expression 
and protein experiments as outlined in table 3.1 and incubated overnight at 37ºC in 
5% v/v CO₂. The next day the medium was aspirated and replaced with 1mL of 
starvation medium (DMEM, 0.4% FCS, L-glutamine, Penicillin/streptomycin or 
Gentamycin) in 12 well plates or 2mL in 6 well plates and incubated overnight. The 
following day the starvation medium was aspirated and cells incubated with 5 ng/mL 
TGF-β1 or TGF-β₂ was made up to 1 mL with starvation medium in each well for 12 
well plates and up to 2 mL/well for 6 well plates. The control wells contained 
2mg/mL BSA vehicle control in starvation medium. Cells were then incubated for 4 
to 48 hr at 37ºC in 5% v/v CO₂ for mRNA expression and from 0-2 h for protein 
measurement. At the appropriate time point cells were harvested for Gli1 and 2 
mRNA and pSMAD2, total SMAD2/3 and α-tubulin protein expression analyses 
according to section 3.6 and 3.7 respectively.  
 
3.4 TGF-β receptor inhibitor studies  
CRL 2081 and MeT-5A cells were used for all TGF-β receptor inhibition and Gli 
studies. As per table 3.1, Met-5A and CRL 2081 cells were seeded in 12 well plates 
at 2.5 x 10
5
 per well and in 6 well plates at 5.0 x 10
5
 for protein expression. The 
CRL2081 cell line represents MM cell line and MeT-5A represents a non-malignant 
mesothelial cell line. Following overnight incubation, the medium was replaced with 
1mL and 2mL starvation medium in 12 well and 6 well plates respectively. The next 
day cells were pre-treated with 20 µM of the TGF-β type 1 receptor (ALK5) 
inhibitor, SB-431542. Cells were also treated with 5-10 µM of the Hh pathway 
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inhibitor cyclopamine to determine if TGF-β-induced Gli expression occurs 
independently of the classic Ptch/SMO-mediated hedgehog pathway. Control wells 
were incubated with the same volume of 100% DMSO or ethanol as vehicle controls 
for the ALK5 inhibitor or cyclopamine respectively. Cells were pre-treated for 1h 
with negative inhibitors followed by stimulation with 5 ng/mL TGF-β₂ for 6 hr for 
mRNA expression and up to 2 h for protein measurement and then lysed according to 
section 3.6.1. The protocol for mRNA expression and protein detection was followed 
as outlined in section 3.6 and 3.7 respectively. 
 
3.5 Transfection of cells 
Cells were seeded for mRNA or protein expression studies as shown in table 3.1. 
After overnight culture, the medium was changed to DMEM with 10% FCS but no 
antibiotics or L-glutamine for at least 45 minute prior to transfection, as outlined in 
table 3.2. 
 
Table 3.2: Volume of medium added to cells prior to transfection according to 
plate type. 
Type of plate Volume of DMEM with 10% FCS, no 
antibiotics or L-glutamine added 
6 well 2800 µL 
12 well 900 µL 
 
 
Cell transfection was performed using two mixtures. The first transfection mixture 
contained appropriate concentrations of SMAD2, SMAD3 or control siRNA made up 
in DMEM (containing no FCS, L-glutamine or antibiotic). The volume of 
transfection mixture per well depended on the type of plate used (outlined in table 
3.4). The second transfection mixture contained Lipofectamine™ 2000 reagent also 
made up in DMEM, and amounts of this mixture used determined by plate size are 
shown in table 3.3. The first and second mixture were combined and incubated for 20 
min at room temperature to allow complexing of the reagents. The total volume of 
mixture as indicated in table 3.4 was then added drop wise to the appropriate well. 
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The plates were gently rocked to combine the mixtures and returned to the incubator. 
The siRNA to SMAD2, SMAD3 and control were initially transfected into cells at a 
final concentration of 1 nM, 10 nM and 20 nM for optimisation experiments. 10 nM 
concentration was subsequently chosen as the optimal concentration for SMAD2 and 
SMAD3 inhibition studies. 
 
Table 3.3: Volume of Lipofectamine™ 2000 made up in DMEM, and total 
volume of the mixture per well according to plate type. 
Plate Lipofectamine™ 
2000/well (µL) 
DMEM/well (µL) Total volume of 
Lipofectamine™ 
2000 + 
DMEM/well (µL)
 
6 well 2 98 100
 
12 well 1 49 50
 
 
 
Table 3.4: Volumes per well used for transfection of cells according to plate 
type. 
Plate Volume of 
transfection 
mixture (µL) 
Volume of 
Lipofectamine™ 
2000 + 
DMEM/well (µL) 
Total volume of 
complexes 
added/well (µL) 
6 well 100 100 200 
12 well 50 50 100 
 
 
At 24 hours following transfection, the medium was aspirated and 0.4% FCS 
starvation medium was added to the cells. The following day, appropriate wells were 
stimulated with TGF-β₂ and the cells lysed for Gli mRNA expression at 6 hr post 
stimulation and phosphorylated and total SMAD2/3 protein measurement at 2 hr as 
per section 3.6.1 and 3.7.1 respectively. 
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3.6 mRNA expression analysis 
Following treatments, cells were lysed and RNA isolated using the Qiagen® RNeasy 
mini kit. The RNA was then converted to cDNA and analysed by Real-Time PCR. 
 
3.6.1 Cell lysis, RNA isolation and quantification 
The medium in 12 well plates was aspirated and 200 µL of the Lysis buffer from the 
RNeasy mini kit was added to each well. A 1% v/v β-mercaptaethanol solution was 
added to the kit lysis buffer immediately before use. All experiments were set up in 
triplicate wells for each treatment and the lysates were combined into one 
microcentrifuge tube. RNA was extracted according to the Qiagen® RNeasy mini kit 
protocol with a minor modification to include DNAse 1 treatment. To degrade any 
DNA contamination in the sample, 350 µL of wash buffer was added to spin 
columns and centrifued at 12 000 x g for 15 sec. The waste was discarded and 80 µL 
of RNase free DNAse 1 solution (section 2.3.1) was added to the spin columns and 
left for 15 min at room temperature. A 350 µL aliquot of wash buffer was added to 
the spin columns and centrifuged at 12 000 x g for 15 sec. The rest of the protocol 
was performed according to the manufacturer’s instructions. RNA was eluted in 50 
µL of RNase free water. The extracted RNA was quantified using a NanoDrop 2000 
spectrophotometer and samples stored at -20ºC until use. 
 
3.6.2 cDNA synthesis 
cDNA was synthesised from RNA using the Qiagen® Omniscript Reverse 
Transcriptase kit. The reaction mixture contained 1 µg of RNA, 1x RT buffer, dNTP 
(500 µM), random hexamer primers (10 µM), RNase inhibitor (10 U), reverse 
transcriptase (4 U) and RNase free water giving a total reaction volume of 20 µL. A 
no template control was also included that contained everything except RNA, which 
was replaced with RNase free water. The cDNA synthesis reaction was carried out at 
37ºC for 60 min in the PCR thermocycler. Samples were stored at -20ºC until use.  
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3.6.3 Real-Time PCR 
Following cDNA synthesis, Real-Time PCR was carried out to determine the levels 
of various mRNAs of interest in the human MM and control cell lines. The reactions 
were performed in duplicate with a total volume of 10 µL per well in a 96 well 
reaction plate. Each reaction contained 1uL of template cDNA, 1x TaqMan® gene 
expression Master Mix, 1x TaqMan® probe and RNase free water. Controls included 
the no template control from the cDNA synthesis, an RNA control (containing 2µL 
of each RNA template used in the cDNA synthesis reaction) to detect any genomic 
DNA contaminations and a water control to detect any real time PCR master mix 
contamination. An adhesive optical film was used to cover the plate and the plate 
centrifuged to collect the samples at the bottom of the wells. The samples were then 
run on the StepOne Plus™ Real-time PCR system. The program consisted of 1 cycle 
each of 50ºC for 2 min followed by 95ºC for 10 min followed by 40 cycles of 95ºC 
for 15 sec and 60ºC for 1 min. The data was collected and stored during the run by 
the StepOne software v2.1. 
 
3.7 Protein analysis (Western blot) 
3.7.1 Protein extraction 
Cells seeded in 6 well plates as previously outlined in table 3.1 were used for protein 
analysis. The medium was aspirated from wells and cells washed twice with ice cold 
1x PBS. SLB++ buffer (section 2.2.6), 220 µL for 100% confluent cells and 110 µL 
for 70-90 confluent cells was then added to the wells. The cells were scraped from 
the plate and the suspension transferred in to a microcentrifuge tube. The tube was 
then vortexed and incubated on ice for 10 min followed by 10 min centrifugation at 
13 000 x g at 4ºC. The supernatant was transferred to a new microcentrifuge tube and 
stored at -20ºC until use. 
 
3.7.2 Protein quantification (Coomassie plus Bradford Assay) 
The Coomassie plus Bradford assay was used to quantify protein samples. Different 
concentrations of BSA were prepared from 2 mg/ml stock BSA and deionised water 
to use as a standard curve. Concentrations of the BSA ranged from 0.05 mg/ml to 
0.75 mg/ml. Protein samples were diluted 1:10 and 1:20 in deionised water and 10 
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µL of that was plated in duplicates in a 96 well plate followed by 200 µL of 
Coomassie plus reagent. Solutions were mixed by tapping the plate then incubated at 
room temperature for 5 min before reading at 595 nm on the Wallac Victor 
Multilable Counter. 
 
3.7.3 Sample preparation 
The concentration of protein in each sample was calculated from the Coomassie plus 
Bradford assay. Samples were thawed at room temperature and the appropriate 
volume of sample required for 10-20 µg of protein was made up to 16 µL with 
deionised water and added to 4 µL of loading buffer, giving a total of 20 µL. The 
tubes were then heated to 95ºC for 10 min and centrifuged briefly. Samples were 
then loaded onto the polyacrylamide gel for electrophoresis. 
 
3.7.4 Gel electrophoresis 
The polyacrylamide gel consisted of a 10% running gel and 6% stacking gel. The 
protein samples were loaded into the wells. A 5 µL Precision Plus protein™ dual 
coloured standard was also loaded. The running tank was then filled with 1x SDS-
PAGE running buffer and run at 180V for approximately 45 min. 
 
3.7.5 Electrophoretic protein transfer 
Once the gel electrophoresis was complete, the PVDF (soaked in methanol for 10 
min) or nitrocellulose transfer membrane, sponges and filter paper, were all soaked 
in 1x transfer buffer for approximately 10 min. A cassette was prepared and the gel 
and membrane were sandwiched between sponge and filter paper with sponge first 
then filter papers, gel, membrane, filter papers, and another sponge. These were all 
sandwiched together after ensuring no air bubbles formed between the gel and the 
membrane. The cassette and an ice block were placed in the transfer tank and the 
tank filled with cold 1x transfer buffer (4ºC). The proteins were transferred at 100v 
for 1.5 hr at room temperature. 
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3.7.6 Protein detection 
After protein transfer was complete, the cassette was dissembled and the membrane 
blocked for 1 hr at room temperature in TBST with 5% skim milk powder (chapter 2, 
Section 2.2.11) to block non-specific binding. The membrane was then washed 4 
times with 1 x TBST (section 2.2.8) for 5 min each before being incubated with the 
primary antibody at 4ºC overnight. Primary antibodies used in this study were diluted 
in 5% skim milk TBST as shown in table 3.5. Following overnight incubation, the 
membrane was washed 4 times in TBST for 5 min each at room temperature and then 
incubated for 1.5 hr in secondary antibody diluted in 1% skim milk TBST as 
described in table 3.5. Membranes were washed 4 times with 1 x TBST for 5 min 
each prior to the addition of Immobilon Western HRP Substrate. Protein bands were 
detected at different exposures with CL-Xposure™ Film using the AGFA developer 
in a CP1000 X-ray processor. 
 
Table 3.5: Dilutions of primary and secondary antibody used for western blot 
analysis 
Primary antibody Dilution used HRP conjugated 
secondary 
antibody 
Dilution used 
α-tubulin 1:15,000 Anti-mouse 1:50,000 
pSMAD2 1:3,000 Anti-rabbit 1:25,000 
pSMAD3 1:3,000 Anti-rabbit 1:25,000 
Total SMAD2/3 1:3,000 Anti-rabbit 1:25,000 
 
 
3.7.7 Membrane Stripping 
Membranes were stripped with two 15 min washes in glycine stripping buffer. The 
membranes were then washed 4 times in 1 x TBST for 5 min each before being 
blocked for 1 hr in 5% skim milk TBST. The membrane was then incubated in 
primary antibody overnight at 4ºC and the western blot process continued as 
described in section 3.7.6. 
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3.7.8 Western blot analysis optimisation 
Following analysis of baseline TGF-β1/2 and Gli1/2 in MM and control cells, 3 MM 
and control MeT-5A cell lines were selected for TGF-β1/2 stimulation studies to 
examine Gli expression. Activity of TGF-β can be measured by examining the 
protein expression of its downstream signalling molecules such as SMAD2/3 and 
specifically the phosphorylation of SMAD2 and SMAD3. For optimisation of 
pSMAD2, pSMAD3 and total SMAD2/3, antibodies for western blot analysis were 
used at various concentrations: primary (1:1,000 to 1:4,000) and secondary (1:1,000 
to 1:5000). 
 
During the optimisation process, it was discovered that the PVDF transfer membrane 
produced excessive background and band fuzziness (figure 3.1 A), therefore I 
decided to use nitrocellulose membranes for all further experiments. Total SMAD2/3 
had to be optimised so that there was a clear separation of the two protein bands. The 
SDS-page gel was initially run at 100V for 2 hr to produce band separation for 
accurate quantitation (figure 3.1 B), but in the later experiments the gel was run at 
180V for 45 min which produced better band separation (figure 3.1 C). 
 
After several optimisation runs it was determined that the best western blot 
conditions were to run the SDS-page gel at 180V for 45 min and the protein transfer 
onto a nitrocellulose membrane and probed with the optimised concentrations of 
primary and secondary antibodies.  
 
 
 
 
 
 
 
 
Figure 3.1 Optimisation of total SMAD2/3 antibody with different western blot 
conditions. (A) SDS page gel run at 100V for 1.5 hr and proteins transferred onto a 
A B 
C 
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PVDF membrane showing fuzziness of the bands and high background. (B) SDS 
page gel run at 100V for 1.5 hr and proteins transferred onto a nitrocellulose 
membrane produced cleaner bands. (C) SDS page gel run at 180V for 45 min and 
proteins transferred onto a nitrocellulose membrane produced clean and crisp bands. 
 
3.8 Surefire protein assay 
3.8.1 Protein quantitation and sample preparation 
Cells were seeded into 6 well plates at optimal seeding densities as outlined in table 
3.1. After overnight incubation at 37ºC, the medium was aspirated from each well 
and 2 mL of starvation medium added. After 16-24 hr incubation the wells were 
stimulated with 5 ng/µL TGF-β₂ and protein lysed using 1 x Lysis buffer supplied by 
the Alphascreen® Surefire® Assay kit. The samples were then incubated on ice for 
10 min before being centrifuged at 12 000 x g for 3 min to pellet insoluble material. 
The supernatants were transferred to a new microcentrifuge tube and stored at -20ºC 
until use. To ensure equal loading of protein, the concentration was quantified using 
a Bradford assay as described in section 3.7.2. A 1µg aliquot of protein for each 
sample was made up to 4 µL in ddH₂O water and added to a Proxiplate 384 well plus 
plate. 
 
3.8.2 Alphascreen® Surefire protein assay 
After the addition of 4 µL of the prepared protein lysates (section 3.7.1) to the 
Proxiplate 384 Plus plate, 5 µL of acceptor mix was added to the wells. The acceptor 
mix contained acceptor beads diluted 1:50 in activation buffer and reaction buffer 
mix (the activation buffer diluted 1:5 in reaction buffer). The plate was then sealed 
with a top seal black adhesive cover, wrapped in aluminium foil and incubated for 2 
hr at room temperature in a dark environment. The plate was then unsealed and 2 µL 
of donor mix containing the donor beads diluted 1:20 in dilution buffer was added to 
the wells. The plate was again resealed with the black adhesive seal and wrapped in 
aluminium foil and incubated at room temperature in a dark environment for 2 hr or 
overnight for better protein detection. The plate was unsealed and fluorescence in 
each sample quantified using the EnSpire plate reader. 
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3.9 Flow Cytometry 
3.9.1 Cell setup and harvest 
Cells were transfected according to section 3.5 with fluorescent labelled siRNA. 
From this point the cells were kept in the dark where possible. After 24 hr of 
incubation, the medium was aspirated and the cells washed twice with 1xPBS. A 50 
µL aliquot of trypsin/EDTA was then added to each well followed by 200 µL of 1 x 
PBS. Once the cells detached from the surface of the well, 50 µL of growth medium 
was added to each well to neutralise the trypsin/EDTA. The suspension was then 
added to 3 mL sterile glass tubes and centrifuged at 1200 for 5 min at room 
temperature. The supernatant was then discarded, the pellet resuspended in 1 mL of 1 
x PBS and centrifuged again at 1200 for 5 min. The supernatant was then removed, 
the pellet resuspended in 500 µL 1 x PBS and the cells immediately examined using 
the Olympus® IX-81® inverted fluorescence microscope. 
 
3.10 Statistical Analysis 
Microsoft Excel and GraphPad Prism 5.0 were used to analyse data. Data is 
presented as mean ± standard error of the mean (SEM) with three or more replicates. 
Statistical analysis was performed by a student’s unpaired t-test or one way analysis 
of variance for multiple comparisons using one way ANOVA. A p value of equal to 
or less than 0.05 was considered to be significant. Data with only two replicates are 
presented as mean. 
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4.1 Cell Morphology 
MM cell lines used in this study were morphologically consistent with those 
previously published (Manning et al., 1991) (figure 4.1). At confluence the 
CRL2081 and LO68 cells expressed a spindled shaped morphology (figure 4.1 A 
and C), whereas JU77, NO36 and VGE cells had a cobblestone, epithelial-like 
morphology at confluence (figure 4.1 B, E and F). The control human transformed 
mesothelial cell line MeT-5A, was also epithelial-like when confluent but had a more 
fibroblastic morphology when sub-confluent, which is consistent with their original 
morphology at isolation (Ke et al., 1989) (figure 4.1 D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Morphology of confluent cell lines. (A) CRL2081 (B) JU77 (C) LO68 
(D) MeT-5A (E) NO36 and (F) VGE cells. Bar = 0.2 mm. 
A B 
C D 
E F 
CRL2081 
LO68 
VGE NO36 
LO68 MeT-5A 
JU77 
MeT-5A 
 
VGE 
0.2 mm 
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4.2 Baseline levels of TGF-β1/2 and Gli1/2 in MM and control cells. 
Baseline levels of TGF-β1/2 and Gli1/2 mRNA were measured in 5 MM cell lines 
and control MeT-5A and primary mesothelial cells by real-time PCR. These cells 
were the once available at the laboratory and thus screened for the baseline levels. 
Determining the basal gene expression levels of TGF-β and Gli in these cells will 
allow comparisons to be made between normal and malignant cells and provide a 
reference point for differences in gene expression for subsequent experiments. 
 
4.2.1 Baseline levels of TGF-β1 and TGF-β2 mRNA in MM and control cells.  
TGF-β plays an important role in modulating the growth and immune function of 
many types of cancer and is also produced by several different cancer cell types 
including MM (Fitzpatrick et al., 1994). In this study the baseline levels of TGF-β1 
and TGF-β2 mRNA in 5 MM and MeT-5A cell lines were compared to control 
normal mesothelial cells. RNA isolated from primary mesothelial cells was kindly 
provided by Ms. Kimberly Birnie in our laboratory. Human PGK-1 was used as an 
endogenous control. The level of TGF-β1 mRNA varied between different MM cell 
lines. MeT-5A, LO68 and JU77 cells had high levels of TGF-β1 mRNA (p-value of 
0.0209, 0.0004 and 0.0018 respectively), while VGE (p-value of 0.0485) and NO36 
had lower TGF-β1 mRNA levels than control mesothelial cells but the difference 
wasn’t significant (figure 4.2). 
 
The level of TGF-β2 mRNA was also measured in all cell lines and control cells. The 
levels were lower in MeT-5A and MM cells compared with control mesothelial cells 
(figure 4.3), but the differences were not significant in other cell lines except 
CRL2081 (p-value of 0.0100). 
 
  
 
63 
P
rim
ar
y
M
eT
-5
A
LO
68
JU
77
C
R
L2
08
1
V
G
E
N
03
6
0
1
2
3
4
*
***
**
*
Cell lines
T
G
F
-
1
 m
R
N
A
 e
x
p
re
s
s
io
n
 
Figure 4.2: Baseline TGF-β1 mRNA levels in MM and control cells. TGF-β1 
mRNA levels were quantified by real time PCR and the results normalised to PGK-1. 
MM and MeT-5A cell lines (dark grey bars) were compared to primary mesothelial 
cells (light grey bar). Data represent the mean of three experiments. Error bars = 
SEM (standard error of mean). *= p ≤ 0.05. **= p ≤ 0.01. ***= p ≤ 0.001.  
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Figure 4.3: Baseline TGF-β2 mRNA levels in MM and control cells. TGF-β2 
mRNA levels were quantified by real time PCR and the results normalised to PGK-1. 
MM and MeT-5A cell lines (dark grey bars). Primary mesothelial cells (light grey 
bar). Data represent the mean of three experiments. Error bars = SEM. *= p ≤ 0.05. 
 
4.2.2 Baseline Gli1 and Gli2 mRNA levels in MM and control cells. 
The effector molecules of the Hh signalling pathway are the Gli transcription factors 
(Forbes et al., 1996). This study measured Gli1 and Gli2 mRNA levels in MM, MeT-
5A and primary mesothelial cells. Gli1 expression was higher in MeT-5A and 4 out 
of 5 MM cell lines compared with primary mesothelial cells (figure 4.4),  although 
the difference was only significant in three MM cell lines, LO68, CRL2081 and 
NO36 (p-value of 0.0022, 0.0085 and 0.0002 respectively). JU77 cells had 
significantly lower Gli1 mRNA levels compared to primary cells (p-value of 0.0101). 
Similarly, Gli2 expression was higher in MeT-5A and 3 out of 5 MM cell lines 
compared to primary mesothelial cells, however only LO68 was significantly 
different (p-value of 0.0128) (figure 4.5). 
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Figure 4.4: Baseline Gli1 mRNA levels in MM and control cells. Gli1 mRNA 
levels were quantified by real time PCR and the results normalised to PGK-1. MM 
and MeT-5A cell lines (green bars) were compared to primary mesothelial cells 
(white bar). Data represent the mean of three experiments. Error bars = SEM. *= p ≤ 
0.05. **= p ≤ 0.01. ***= p ≤ 0.001. 
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Figure 4.5: Baseline Gli2 mRNA levels in MM and control cells. Gli2 mRNA 
levels were quantified by real time PCR and the results normalised to PGK-1. The 
MM and MeT-5A cell lines (maroon bars) were compared to primary mesothelial 
cells (white bar). Data represent the mean of three experiments.  Error bars = SEM. 
*= p ≤ 0.05.  
 
4.3 Confirmation of TGF-β1 and TGF-β2 activity.  
TGF-β is known to induce phosphorylation of SMAD2 and SMAD3 and TGF-β1 is 
known to stimulate the production of many extracellular matrix (ECM) proteins 
including collagen type-1 (Ignotz & Massague, 1986). Therefore, I wanted to see if 
my preparation of recombinant TGF-β1/2 induced phosphorylation of SMAD2 and 
stimulated collagen type-1α1 mRNA production in one of my MM cell lines JU77.  
Based on previous studies in my laboratory and from published data, I expected 
pSMAD2 increase over time with TGF-β stimulation and maximal collagen mRNA 
expression at 24 hr, therefore this confirmation experiments were done on the cell 
line previously shown to be inducing this.  
 
4.3.1 TGF-β signalling is mediated by the SMAD2/3 pathway in MM cells. 
The SMAD proteins transmit signals from the TGF-β receptors at the cell membrane 
to the nucleus and initiating transcription of TGF-β target genes (Massague et al., 
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2000). Based on previous findings and antibody database, the cells were incubated 
with recombinant TGF-β2 and protein isolated at 0, 1/2, 1 and 2hrs. JU77 cells were 
treated with 5 ng/mL TGF-β1 for up to 2 hr and results compared with untreated 
control. TGF-β1 induced an increase in pSMAD2 over time as expected confirming 
activity of the TGF-β1 preparation I was using (figure 4.6 A). MM and MeT-5A cells 
were incubated with recombinant TGF-β2 for 30, 60 and 120 min and pSMAD2 and 
total SMAD2/3 protein examined by western blot. All three cell lines showed 
significant induction of pSMAD2 in response to TGF-β2 stimulation within 2 hr of 
stimulation (figure 4.8 A, B, C and D). 
 
4.3.2 TGF-β induces human collagen type-1α1 mRNA expression in MM and 
control cells. 
For collagen mRNA expression, cells were stimulated with TGF-β1 or TGF-β2 for 6, 
24 and 48 hr. Using JU77 cells, TGF-β1 significantly upregulated collagen type-1α1 
mRNA at 24 hr compared with unstimulated control (p-value of 0.0168) (figure 4.6 
B), similar observations were made with JU77 cells stimulated with TGF-β2 (figure 
4.7). These results were consistent with previous findings in my laboratory. 
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Figure 4.6: TGF-β1 induces the expression of human collagen type-1α1 mRNA 
and pSMAD2 in JU77 cells. (A) pSMAD2 and total SMAD2/3 protein expression 
were determined by western blot following 30 min 1h and 2hr TGF-β1 stimulation. 
Data represents one experiment. (B) Collagen type-1α1 mRNA levels were 
quantified by real time PCR and the results normalised to PGK-1.  Data is presented 
as fold change above control at three different time points. Red bars show expression 
at 6 hr, green bars show expression at 24 hr and blue bars show expression at 48 hr. 
Data represents the mean of three experiments. Error bars = SEM. Significance 
compared to respective control: *= p ≤ 0.05.  
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Figure 4.7: TGF-β2 induces human collagen type-1α1 mRNA in MM and 
control cells. The data is presented as fold change for each cell line at three different 
time points (6, 24 and 48 hr) compared with their unstimulated controls. mRNA 
levels were quantified by real time PCR and the results normalised to PGK-1.  Red 
bars show expression at 6hr, green bars show expression at 24hr and blue bars show 
expression at 48hr. Each bar represents one experiment. 
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Figure 4.8: TGF-β2 induces phosphorylation of SMAD2 in MM and MeT-5A 
cells. Total SMAD2/3 and pSMAD2 was examined by western blot 2 h after TGF-β2 
stimulation. White bars show unstimulated control. Pink bars show TGF-β2 
stimulated cells. (A) Representative western blot for pSMAD2 and total SMAD2/3. 
pSMAD2 expression was normalised to total SMAD2/3 by densitometry for (B) 
CRL2081 (C) LO68 and (D) MeT-5A. Data represent the mean of three experiments. 
Error bars = SEM. Significance compared to control: *= p ≤ 0.05. **= p ≤ 0.01. 
***= p ≤ 0.001.  
 
 
4.4 The effect of TGF-β1 and TGF-β2 on Gli1 and Gli2 mRNA levels in MM and 
control cells. 
Recent studies have shown an interaction between Hh and TGF-β signalling 
pathways in a variety of cell types (Dennler et al., 2007). This interaction occurs 
downstream of SMO and targets Gli2 in some normal and malignant cell types 
(Alexaki et al., 2010). Gli1 expression is subsequently activated in a Gli2 dependent 
manner (Dennler et al., 2007). Therefore in this study the effect of TGF-β1 and TGF-
β2 on Gli1 and Gli2 mRNA levels were examined in MM and control MeT-5A cells 
at various times. LO68 cells were selected as they showed high expression of Gli1 
and Gli2 mRNA expression, whereas JU77 cells showed low levels and CRl2081 
cells displayed variable levels. The earlier time point (4-6hr) was set to examine 
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early Gli2 expression while the later time points (24 and 48hr) for the subsequent 
Gli1 expression. 
 
 
4.4.1 Effect of TGF-β1 on Gli1 and Gli2 MM and control cells. 
TGF-β1 and TGF-β2 are both important for MM growth (Kuwahara et al., 2001), 
therefore in this study the effect of both TGF-β isoforms on Gli1 and Gli2 mRNA 
levels in MM and control cells were examined. 
 
Figure 4.9 and 4.10 show relative Gli1 and Gli2 mRNA levels after TGF-β1 
stimulation in MM and MeT-5A cells at 6, 24 and 48 hr. TGF-β1 did not increase 
Gli1 or Gli2 mRNA levels in any of the cell lines when compared with unstimulated 
controls. In fact there was a significant decrease in Gli1 mRNA levels at 24 h 
compared to control in LO68 cells (p value of 0.0134) but this was due to high levels 
of Gli1 mRNA in the 24 hr control. 
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Figure 4.9: TGF-β1 does not stimulate an increase in Gli1 mRNA levels in MM 
and control cells. Gli1 mRNA levels were quantified by real time PCR and the 
results normalised to PGK-1. White bars show unstimulated cells. Green bars show 
TGF-β1 stimulated cells. Data is presented as mRNA expression at 6, 24 and 48 h 
after TGF-β1 stimulations in (A) CRL2081 (B) JU77 (C) LO68 and (D) MeT-5A 
cells. Data represent the mean of three experiments. Error bars = SEM. Significance 
compared to untreated control: *= p ≤ 0.05. Abbreviations: control (C). 
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Figure 4.10: TGF-β1 does not increase Gli2 mRNA levels in MM and control 
cells. Gli2 mRNA levels were quantified by real time PCR and the results normalised 
to PGK-1. White bars show unstimulated cells. Red bars show TGF-β1 stimulated 
cells. Data is presented as mRNA expression at 6, 24 and 48 h after TGF-β1 
treatment in (A) CRL2081 (B) JU77 (C) LO68 and (D) MeT-5A cells. Data 
represent the mean of three experiments. Error bars = SEM.  
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4.4.2 Effect of TGF-β2 on Gli1 and Gli2 expression in MM and control cells. 
The effect of TGF-β2 on Gli1 and Gli2 mRNA was examined in three MM and 
control MeT-5A cell lines at 4, 6, 24 and 48 hr. TGF-β2 had no effect on Gli1 mRNA 
expression compared to unstimulated controls in all cell lines tested (figure 4.11). 
Interestingly, Gli1 mRNA levels were high in the control samples at 24 hr consistent 
with the observations made with TGF-β1 stimulations. TGF-β2 caused a significant 
down regulation of Gli1 mRNA levels in MeT-5A cells at 24 hr compared to its 
unstimulated control (p-value of 0.0242).  
 
TGF-β2 stimulated a significant increase in Gli2 mRNA levels at 4-6 hr in all of the 
cell lines, including control MeT-5A cells (figure 4.12). A 2.5 and 3 fold increase in 
Gli2 mRNA expression was observed in CRL2081 and MeT-5A cell lines (p-value 
of 0.02 and 0.0039 respectively) at 6 h and approximately a 2 fold change in LO68 
and JU77 cells at 4h (p-value of 0.0179 and 0.0367 respectively). CRL2081 and 
control MeT-5A cell lines were subsequently selected for further studies. 
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Figure 4.11: TGF-β2 does not increase Gli1 mRNA levels in MM and control 
cells. Gli1 mRNA levels were quantified by real time PCR and the results normalised 
to PGK-1. White bars show unstimulated cells. Green bars show TGF-β2 stimulated 
cells. Data is presented as mRNA expression at 4, 6, 24 and 48h in (A) CRL2081 (B) 
JU77 (C) LO68 and (D) MeT-5A cells. Data represent the mean of three 
experiments.  Error bars = SEM. Significance compared to respective controls: *= p 
≤ 0.05.  
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Figure 4.12: TGF-β2 stimulated upregulation of Gli2 mRNA in all cell types. 
Gli2 mRNA levels were quantified by real time PCR and the results normalised to 
PGK-1.  White bars show unstimulated cells. Red bars show TGF-β2 stimulated 
cells. Data is expressed as mRNA expression in (A) CRL2081 (B) JU77 (C) LO68 
and (D) MeT-5A cells. Data represent the mean of three experiments. Error bars = 
SEM. Significance compared to respective controls: *= p ≤ 0.05.  
 
 
4.4.3 Effect of TGF-β2 on Ptch1 mRNA expression in CRL2081 and control 
cells. 
Several studies have shown Ptch1 to be a target gene for Gli1 (Cigna et al., 2012), 
and Gli2 (Kim et al., 2007: Regl et al., 2004: Lipinski et al., 2008). In this study I 
examined the effect of TGF-β2 on Ptch1 mRNA levels in CRL2081 and MeT-5A 
cells 24 hr and 48 hr post treatment by real-time PCR. CRL2082 cells were selected 
as they showed greater response with TGF-β2 for Gli2 mRNA expression, and the 
MeT-5A cells served as control. Ptch1 mRNA levels did not change at 24 h but 
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increased at 48h compared to control in both the cell lines (figure 4.13), but was only 
significant in MeT-5A cells (p-value of 0.0127).  
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Figure 4.13: Ptch1 expression after TGF-β2 treatment in CRL2081 and MeT-5A 
cells. Ptch1 mRNA levels were measured by real time PCR and the results 
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normalised to PGK-1. White bars show unstimulated cells. Blue bars show TGF-β2 
stimulated cells. Data is expressed as mRNA expression for (A) CRL2081 and (B) 
MeT-5A cells. Bars represent the mean of three experiments. Error bars = SEM. *= p 
≤ 0.05. 
 
CRL2081 and MeT-5A cell lines were selected for further inhibition studies. As 
CRL2081 had highest Gli2 activation after TGF-β2 stimulation and MeT-5A served 
as a non-malignant control cell line. 
 
 
4.5 Effect of blocking TGF-β receptor on Gli2 expression. 
MM cells produce TGF-β (Marzo et al., 1997). Therefore to further explore the 
potential interaction between TGF-β and Hh pathways in MM cells, I examined the 
effect of blocking TGF-β2 signalling on Gli2 mRNA levels. ALK5 receptor inhibitor 
SB-431542 compound was used to block the TGFβRI/ALK5 receptor which 
mediates TGF-β signalling in a wide range of cell types (Ebner et al., 1993). 
Blocking TGFβRI/ALK5 should inhibit TGF-β2 mediated phosphorylation of 
SMAD2/3, preventing transcription of TGF-β2 target genes including Gli2 (Inman et 
al., 2002).  
 
 
4.5.1 SB-431542 reduced phospho-SMAD2 protein in CRL2081 and MeT-5A 
cells.  
To confirm that inhibiting the TGF-β2 receptor complex abrogated downstream 
signalling, I examined pSMAD2 by western blot analysis. Incubation of CRL2081 
and MeT-5A cells with TGF-β2 lead to robust induction of pSMAD2 which was 
inhibited when cells were pretreated with SB-431542 prior to TGF-β2 exposure. 
Figure 4.14 A shows a western blot of CRL2081 and MeT-5A cells treated with SB-
431542 and DMSO control in the presence or absence of TGF-β2 and assessed for 
pSMAD2, total SMAD2/3 and α-tubulin. As shown is figure 4.14 B and C there was 
a 4.2 fold inhibition of pSMAD2 in CRL2081 cells pretreated with SB-431542 then 
treated with TGF-β2 and a 15.3 fold decrease in MeT-5A cells.  
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Figure 4.14: SB-431542 inhibits pSMAD2 protein expression in CRL2081 and 
MeT-5A cells. pSMAD2 and total SMAD2/3 levels were assessed by western blot. 
α-tubulin was used as a lane loading control. White bars show treatment in the 
absence of TGF-β2. Orange bars show TGF-β2 stimulated cells. (A) Western blots 
showing pSMAD2, total SMAD2/3 and α-tubulin expression for CRL2081 and MeT-
5A cells. Densitometric analysis showing pSMAD2 normalised against total 
SMAD2/3 for (B) CRL2081 and (C) MeT-5A. Each bar represents the mean of two 
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experiments. Abbreviations: ALK5 inh (ALK5 inhibitor-SB431542), TB2 (TGF-
β2). 
 
 
4.5.2 SB-431542 blocks TGF-β2-mediated Gli2 mRNA expression in CRL2081 
and MeT-5A cell lines. 
Initial studies optimised SB-431542 inhibition of TGF-β signalling by treating cells 
with different concentrations of the inhibitor. The optimal concentration was 20 µM  
and therefore this concentration was used in all subsequent studies (figure 4.15). 
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Figure 4.15: Optimisation of SB-431542 treatment in CRL2081 cells. Gli2 
mRNA was quantified by real-time PCR and the results normalised to PGK-1. White 
bars show controls and red bars show different concentration of SB-431542 treated 
cells. Data is presented as mRNA expression. Each bar represents one experiment. 
Abbreviations: ALK5 inhibitor – SB431542 (SB). 
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CRL2081 and MeT-5A cells were pretreated with SB-431542 or its vehicle control 
for 1h then stimulated with TGF-β2. After 6hr the cells were harvested and Gli2 
mRNA expression was analysed. Consistent with previous findings both CRL2081 
and MeT-5A cells showed significant Gli2 induction by TGF-β2 compared to its 
DMSO or untreated controls (p-value of 0.0254, 0.0328 and 0.0269 respectively). 
Gli2 mRNA expression levels in cells treated with SB-431542 in presence or absence 
of TGF-β2 was compared to cells treated with vehicle control stimulated with TGF-
β2. SB-431542 significantly suppressed TGF-β2 induced Gli2 mRNA expression in 
both cell lines (figure 4.16) (p-value of 0.0458 and 0.0248 in CRL2081 cells and 
0.0010 and 0.0107 in MeT-5A cells).  
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Figure 4.16: SB-431542 abrogates TGF-β2-induced Gli2 mRNA expression. Gli2 
mRNA was quantified by real time PCR and the results normalised to PGK-1. White 
bars show different treatments and red bars show cells with different treatments and 
stimulated with TGF-β2. Data is presented as relative expression for (A) CRL2081 
and (B) MeT-5A cells. Data represents the mean of three experiments. Error bars = 
SEM. Significance compared to TGF-β2 unstimulated controls: *= p ≤ 0.05. 
Significance compared to cells treated with DMSO + TGF-β2: ^= p ≤ 0.05. ^ ^ ^= p ≤ 
0.001. 
 
4.6 Effect of blocking the SMAD2/3 pathway on TGF-β2 induced Gli2 
expression. 
To determine if the SMAD2/3 pathway is involved in TGF-β2 mediated Gli2 
expression in MeT-5A and CRL2081 cells, SMAD signalling was blocked using 
siRNA to SMAD2/3 genes. The concentration of siRNA was optimised to 
successfully knock down SMAD2 and SMAD3 mRNA and protein in MeT-5A cells. 
Cells were then transfected with siRNA against SMAD2 or SMAD3 and treated with 
TGF-β2. Gli2 mRNA expression was evaluated by real-time PCR and pSMAD2 and 
total SMAD2/3 protein expression was assessed by western blot. 
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4.6.1 Optimisation of siRNA concentrations to block SMAD2 and SMAD3  
siRNA concentrations were optimised in MeT-5A cells. Cells were transfected with 
1, 10 or 20 nM siRNA against SMAD2 or SMAD3. The SMAD2 and SMAD3 
mRNA and pSMAD2 and total SMAD2/3 protein were measured after 48 hr. As 
shown in figure 4.17. Transfection of 10nM SMAD2 or SMAD3 siRNA resulted in a 
3.2 fold reduction in SMAD2 mRNA and a 4.3 fold reduction in SMAD3 
respectively relative to controls. At 20nM siRNA there was non-specific suppression 
of SMAD targets. Therefore 10nM siRNA was used for all subsequent experiments. 
 
The specificity of the siRNA knockdown was further investigated by analysing 
SMAD2/3 protein expression by western blot. Figure 4.18 A shows western blot of 
MeT-5A cells treated with 10 and 20nM siRNA to SMAD2 and SMAD3 and 
assessed for pSMAD2, total SMAD2/3 and α-tubulin protein expression. Treatment 
of cells with 10nM SMAD2 siRNA knocked down pSMAD2 and total SMAD2 
proteins by 50% compared with control (figure 4.18 B and C), and SMAD3 siRNA 
knocked down approximately 40% total SMAD3 protein (figure 4.18 D). Consistent 
with mRNA data, treatment of MeT-5A cells with 20nM siRNA led to a non-specific 
decrease in pSMAD2 protein.  
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Figure 4.17: SMAD2 and SMAD3 siRNA at 10nM effectively supressed 
SMAD2/3 mRNA in MeT-5A cells. SMAD2/3 mRNA levels were quantified by 
real time PCR and the results normalised to PGK-1. White bars show untransfected 
or control siRNA transfected cells. Purple and green bars show siRNA transfected 
cells. Data is presented as mRNA expression of (A) SMAD2 and (B) SMAD3. Data 
represents the mean of two repeat experiments. Abbreviations: control siRNA (cont), 
SMAD2 siRNA (si SD2) and SMAD3 siRNA (si SD3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
pSMAD2 
Total SMAD2/3 
α-tubulin 
N
o
 s
iR
N
A
 
C
o
n
t 
1
0
n
M
 
s
i 
S
D
2
 1
0
n
M
 
s
i 
S
D
3
 1
0
n
M
 
C
o
n
t 
2
0
n
M
 
s
i 
S
D
2
 2
0
n
M
 
s
i 
S
D
3
 2
0
n
M
 
60 kDa 
60 kDa 
52 kDa 
50 kDa 
N
o
 s
iR
N
A
 
C
o
n
t 
1
0
n
M
 
s
i 
S
D
2
 1
0
n
M
 
s
i 
S
D
3
 1
0
n
M
 
C
o
n
t 
2
0
n
M
 
s
i 
S
D
2
 2
0
n
M
 
s
i 
S
D
3
 2
0
n
M
 
Experiment 1 Experiment 2 
 
A 
  
 
86 
no
 s
iR
N
A
co
nt
 1
0n
M
si
 S
D
2 
10
nM
si
 S
D
3 
10
nM
co
nt
 2
0n
M
si
 S
D
2 
20
nM
si
 S
D
3 
20
nM
0.0
0.5
1.0
1.5
B
Treatment
R
a
ti
o
 o
f 
p
S
M
A
D
2
n
o
rm
a
li
s
e
d
 t
o

-t
u
b
u
li
n
 
no
 s
iR
N
A
co
nt
 1
0n
M
si
 S
D
2 
10
nM
si
 S
D
3 
10
nM
co
nt
 2
0n
M
si
 S
D
2 
20
nM
si
 S
D
3 
20
nM
0.0
0.5
1.0
1.5C
Treatment
R
a
ti
o
 o
f 
to
ta
l 
S
M
A
D
2
n
o
rm
a
li
s
e
d
 t
o

-t
u
b
u
li
n
 
no
 s
iR
N
A
co
nt
 1
0n
M
si
 S
D
2 
10
nM
si
 S
D
3 
10
nM
co
nt
 2
0n
M
si
 S
D
2 
20
nM
si
 S
D
3 
20
nM
0.0
0.1
0.2
0.3
0.4D
Treatment
R
a
ti
o
 o
f 
to
ta
l 
S
M
A
D
3
n
o
rm
a
li
s
e
d
 t
o

-t
u
b
u
li
n
 
Figure 4.18: SMAD2 and SMAD3 siRNA suppressed pSMAD2 and total 
SMAD2/3 protein expression in MeT-5A cells. pSMAD2 and total SMAD2/3 
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levels were examined by western blot analysis. α-tubulin was used as an endogenous 
and lane loading control. White bars show untransfected or control siRNA 
transfected cells. Purple and green bars show siRNA transfections. (A) Western blot 
showing pSMAD2, total SMAD2/3 and α-tubulin expression inMeT-5A cells. 
Densitometric analysis showing pSMAD2 (B), total SMAD2 (C) and total SMAD3 
(D) expression was normalised against α-tubulin. Each bar represents the mean of 
two experiments.  
 
4.6.2 Validation of SMAD2/3 mRNA expression knockdown.  
The effect of SMAD2 and SMAD3 siRNA on SMAD2 and SMAD3 mRNA levels 
was examined in CRL2081 and MeT-5A cells. Transfection with SMAD2 and 
SMAD3 siRNA reduced the basal levels of SMAD2 and SMAD3 respectively 
compared to control siRNA (figure 4.19).  
 
SMAD2 siRNA reduced SMAD2 mRNA levels by 60% in CRL2081 cells (figure 
4.19 A), and by 50% in MeT-5A cells (figure 4.19 B) (p-value of 0.0409 and 0.0060 
respectively). SMAD3 siRNA reduced SMAD3 mRNA levels by 45% in CRL2081 
cells (figure 4.19 C) and approximately 40% in MeT-5A cells (figure 4.19 D) (p-
value of 0.0384 and 0.0321 respectively). Similar effects were observed when 
combining siRNAs to SMAD2/3. In CRL2081 cells SMAD2/3 siRNA reduced 
SMAD2 mRNA levels by 50% and by 60% in MeT-5A cells (figure 4.18 A and B) 
(p-value of 0.0500 and 0.0076 respectively). There was approximately 30% 
inhibition in SMAD3 mRNA levels in CRL2081 cells and 60% in MeT-5A cells with 
combined SMAD2/3 siRNA (figure 4.19 C and D). 
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Figure 4.19: SMAD2 and SMAD3 siRNA supresses SMAD2/3 mRNA in 
CRL2081 and MeT-5A cells. Cells were transfected with siRNA against SMAD2 or 
SMAD3 (coloured bars) or controls (white bars). SMAD2 and SMAD3 mRNA 
levels were quantified by real time PCR and the results normalised to PGK-1. Data is 
presented as mRNA expression of SMAD2 in (A) CRL2081 and (B) MeT-5A and 
SMAD3 in (C) CRL2081 and (D) MeT-5A. Data represent the mean of four 
experiments. Error bars = SEM. Significance compared control siRNA transfected 
cells: *= p ≤ 0.05. Abbreviations: Control siRNA (Cont siRNA), SMAD2 siRNA (si 
SD2), SMAD3 siRNA (si SD3), SMAD2 and SMAD3 siRNA (si SD 2/3). 
 
4.6.3: Validation of SMAD2/3 protein expression knockdown. 
To confirm that siRNA to SMAD2 and SMAD3 inhibits SMAD proteins, CRL2081 
and MeT-5A cells transfected with SMAD2 and SMAD3 siRNA and total and 
pSMAD2 and pSMAD3 proteins analysed by western blot. These cells were also 
stimulated with TGF-β2 after SMAD2 and SMAD3 siRNA transfections to examine 
reduction in pSMAD2 and pSMAD3 proteins compared to TGF-β2 induced levels. 
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Staining for α-tubulin was used as an endogenous control and lane loading control. 
Phosphorylated SMAD2 and SMAD3 were reduced when cells were transfected with 
siRNA to SMAD2 and SMAD3 respectively (figure 4.20 A and 4.21 A). SMAD 
siRNAs also knocked down TGF-β2 mediated pSMAD2 and total SMAD2/3 
respectively. However the knock down was only around 40-50% for phosphorylated 
SMAD2 (figure 4.20 B and 4.21 B) and 25% for SMAD3 (figure 4.20 C and 4.21 
C) compared with controls for both cell lines. In both cell lines, partial knockdown 
of total SMAD2 and SMAD3 protein was also observed with respective siRNAs 
(figure 4.20 and 4.21 C and D).  
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Figure 4.20: SMAD2 and SMAD3 siRNA transfections shows a trend towards 
reduced pSMAD2/3 and total SMAD2/3 protein in CRL2081 cells. Coloured bars 
show transfections followed by TGF-β2 stimulation. White bars show treatment in 
the absence of TGF-β2. (A) Western blots for pSMAD2, total SMAD2/3 and α-
tubulin loading control. Densitometric analysis showing pSMAD2 (B), pSMAD3 
(C), total SMAD2 (D) and total SMAD3 (E) normalised to α-tubulin. Data represent 
mean of two experiments.  
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Figure 4.21: SMAD2 and SMAD3 siRNA transfections shows a trend towards 
reduced pSMAD2/3 and total SMAD2/3 protein in MeT-5A cells. Coloured bars 
show transfections followed by TGF-β2 stimulation. White bars show controls in the 
absence of TGF-β2.  (A) Western blots for pSMAD2, total SMAD2/3 and α-tubulin 
loading control. Densitometric analysis showing pSMAD2 (B), pSMAD3 (C), total 
SMAD2 (D) and total SMAD3 (E) normalised to α-tubulin. Data represent mean of 
two experiments. Abbreviations: No siRNA (No si), Control siRNA (Cont si). 
 
 
4.6.4 Gli2 induction by TGF-β2 is SMAD2/3 dependent. 
To determine if TGF-β2-induced Gli2 expression is SMAD2/3 dependent, CRL2081 
and MeT-5A cells were transfected with 10nM siRNA to SMAD2, SMAD3 or 
control siRNA treated with TGF-β2 and Gli2 mRNA levels measured. Following 
TGF-β2 treatment, there was strong induction of Gli2 mRNA in both cell lines.  This 
induction was reduced when the cells were transfected with SMAD2 or SMAD3 
siRNA (figure TGF4.22). SMAD2 and SMAD3 siRNA showed greatest inhibition 
of Gli2 mRNA expression in CRL2081 cells (p-value of 0.0093 and 0.0044 
respectively) (figure 4.22 A). Although there was a trend for a decrease in Gli2 
levels in MeT5A cells transfected with SMAD2 and SMAD3 siRNA (figure 4.22 B).  
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Figure 4.22: SMAD2 and SMAD3 siRNA suppress TGF-β2-mediated Gli2 
mRNA expression in CRL2081 and shows a trend towards a decrease in MeT-
5A cells. Gli2 mRNA levels were quantified by real time PCR and the results 
normalised to PGK-1. Cells transfected with siRNA targeting SMAD2, SMAD3 or 
control siRNA were treated with TGF-β2 (red bars) or left untreated (white bars) and 
Gli2 mRNA levels measured. Data is presented as mRNA expression for (A) 
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CRL2081 and (B) MeT-5A cells. Data represents the mean of four experiments. 
Error bars = SEM. Significance compared to TGF-β2 unstimulated controls: *= p ≤ 
0.05. Significance compared control siRNA transfected and TGF-β2 treated cells: ^= 
p ≤ 0.05. ^ ^= p ≤ 0.01.  
 
4.6.5 Transfection efficiency of siRNA in CRL2081 and MeT-5A cells. 
As the knockdown effects of siRNA to SMAD2 and SMAD3 were only moderate, I 
wanted to measure the transfection efficiency in the cell lines. The SMAD2/3 siRNA 
used in the study did not have a label that could be used to assess transfection 
efficiency. Therefore I transfected cells with control siRNA containing a fluorescein 
conjugate (FITC) designed to measure transfection efficiency. FITC is a light 
reactive dye that can be quantified by FACS analysis. Similar to other siRNA 
transfection experiments, 10nM FITC labelled control siRNA was transfected into 
cells and efficiency assessed 24 hr after transfection. The cell population was gated 
based on the dimensions and complexity of the cells analysed (figure 4.23 A for 
CRL2081 and figure 4.24 A for MeT-5A cells). The cell population was separated 
into FITC negative and FITC positive cells using untransfected cells as negative 
controls (figure 4.23 B and C for CRL2081 and figure 4.24 B and C for MeT-5A 
cells). Transfection was only about 6% in CRL2081 and 27% in MeT-5A cells 
(figure 4.23 D and 4.24 D). 
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Figure 4.23: Transfection efficiency of FITC labelled control siRNA in 
CRL2081 cells. The percentage of cells expressing FITC label was determined. (A) 
representative scatter plot showing side scatter height (SCC-H) verses forward 
scatter height (FSC-H) and gating the cell population and creating a (B) histogram of 
FITC fluorescence intensity showing an untransfected cell population and the gating 
for FITC positive cells and (C) histogram of FITC fluorescence intensity showing 
transfected cell population and gating for FITC positive cells. (D) Percentage of 
FITC positive cells. Data is the mean of three wells in one experiment. Error bars = 
SEM. 
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Figure 4.24: Transfection efficiency of FITC labelled control siRNA in MeT-5A 
cells. The percentage of cells expressing FITC fluorescence intensity was 
determined. (A) Representative dot points plotting side scatter height (SCC-H) verses 
forward scatter height (FSC-H) and gating the cell population and creating a (B) 
histogram of FITC fluorescence intensity showing an untransfected cell population 
and the gating for FITC positive cells and (C) histogram of FITC fluorescence 
intensity showing transfected cell population and gating for FITC positive cells. (D) 
Percentage of FITC positive cells. Data is the mean of three wells in one experiment. 
Error bars = SEM. 
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4.7 Effect of cyclopamine on TGF-β2 mediated Gli2 expression in cell lines. 
Studies in different tours have shown that induction of Gli by TGF-β is independent 
of Hh signalling (through Ptch/Smo axis) (Dennler et al., 2007). To determine if 
TGF-β2-induced Gli2 is also independent of Hh signalling in MM, cells were treated 
with TGF-β2 in presence or absence of cyclopamine (a SMO inhibitor) and Gli2 
mRNA levels measured. If TGF-β2-induced Gli2 upregulation is independent of Hh 
signalling, cyclopamine will have no effect on induction of Gli2.  
 
 
4.7.1 Effect of cyclopamine on TGF-β2 mediated Gli2 mRNA expression 
The effect of blocking Hh signalling with cyclopamine on TGF-β2-mediated Gli2 
mRNA expression was examined in MM and control cells. As shown in figure 4.25, 
samples pretreated with vehicle control then stimulated with TGF-β2 had an 
unexpected reduction in Gli2 mRNA levels in both MeT-5A and CRL2081 cells. 
Although cyclopamine treated cells had reduced Gli2 mRNA, no conclusion could be 
drawn from this experiment. Further optimisation studies are required to eliminate 
the effect of the control before the effect of blocking the Hh pathway on TGF-β2-
induced Gli2 mRNA can be adequately assessed.  
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Figure 4.25: Cyclopamine and vehicle control reduced TGF-β2 induced Gli2 
expression in CRL2081 and MeT-5A cells. CRL2081 and MeT-5A cells were 
treated with cyclopamine and controls and then stimulated with TGF-β2. Gli2 mRNA 
was quantified by real time PCR and the results normalised to PGK-1. White bars 
show treated cells in the absence of TGF-β2. Red bars show treated stimulated with 
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TGF-β2. Data is presented as mRNA expression (A) MeT-5A and (B) CRL2081 
cells. Data represents mean of two experiments in MeT-5A and one experiment in 
CRL2081 cells. Abbreviations: Cyclopamine (Cyclo).  
 
 
4.7.2 Effect of cyclopamine on Ptch1 expression in MeT-5A cells. 
As cyclopamine and the vehicle control affected Gli2 levels, I examined their effect 
on another target gene Ptch1. MeT-5A cells were selected as these served as the 
control cells, and I wanted to investigate the effect of cyclopamine in these cells 
before progressing to MM cells. MeT-5A cells were pretreated with cyclopamine or 
vehicle control for 1h before incubation with TGF-β2. Ptch1 mRNA expression 
levels were then measured after 6 hr. Ptch1 levels were reduced by 5 µM but not the 
10 µM cyclopamine compared with the vehicle treated controls but this effect was 
restored in the presence of TGF-β2 (figure 4.26). Further experiments need to be 
performed to confirm this observation. 
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Figure 4.26: Treatment with cyclopamine down regulated Ptch1 expression in 
MeT-5A cells.  MeT-5A cells were treated with cyclopamine or vehicle control, 
stimulated with TGF-β2 and Ptch1 mRNA levels quantified by real time PCR. The 
results were normalised to PGK-1. White bars show treated cells without TGF-β2 
stimulation. . Blue bars show treated cells with TGF-β2 stimulation. Data represents 
the mean of two repeat experiments.  
 
 
4.8 Quantitative measurement of pSMAD2 protein using alphascreeen® 
Surefire® technology. 
The Alphascreen® Surefire® technology by Perkin and Elmer is a recently 
developed method used to quantify signalling proteins within cell lysates. This 
technique requires less protein and is fully quantitative rather than the semi-
quantitative western blots technique. This method was used to generate a quantitative 
measure of pSMAD2 protein levels expressed in cell lysates and to support the 
western blot data. The pSMAD2 units obtained from the assay were divided by those 
of GAPDH or Histone endogenous control to obtain a ratio. 
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4.8.1 Quantitative analysis of pSMAD2 using Alphascreen analysis. 
To optimise the assay for measuring pSMAD2 levels using Alphascreen technology, 
the MeT-5A cells were stimulated with TGF-β2 and lysed at different time points. I 
wanted to firstly investigate the effect in MeT-5A cells for the optimization 
experiments. GAPDH protein expression was used as an endogenous control to 
normalize levels of pSMAD2 protein. Results show a trend towards an increase in 
the expression of pSMAD2 in TGF-β2 stimulated cells over time compared with 
unstimulated control (figure 4.27), but the increase was only observed at 2 hr (1.8 
fold increase p-value 0.0230). This increase was less than the results obtained by 
western blot analysis (4.5 fold change in pSMAD2 at 2 hr compared to unstimulated 
control) (figure 4.8). 
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Figure 4.27: pSMAD2 protein levels normalised to GAPDH in MeT-5A cells 
using Alphascreen technology. pSMAD2 protein expression following TGF-β2  
stimulation normalised to GAPDH detected using the Surefire® assay. White bar 
shows unstimulated control. Green bars show TGF-β2 stimulated cells. Data 
represent the mean of three experiments. Error bars = SEM. Significance compared 
to untreated control: *= p ≤ 0.05. 
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4.8.2 pSMAD2 levels normalised to Histone in MeT-5A cells. 
For MM cells GAPDH may not be the most suitable endogenous control as previous 
unpublished data in our laboratory showed that GAPDH levels can change upon 
different treatments. Therefore, data was normalised to Histone levels and expressed 
as a ratio. There was no significant change in the level of pSMAD2 in MeT-5A cells 
at any of the time points examined compared with unstimulated control (figure 
4.28). In contrast, western blot analysis revealed an increase in pSMAD2 over time 
(figure 4.8). Further examination of the result showed that there was a high variation 
in Histone expression, which skewed the data.  
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Figure 4.28: pSMAD2 protein levels normalised to Histone in MeT-5A cells 
using Alphascreen technology. pSMAD2 protein expression following TGF-β2  
stimulation normalised to Histone. White bar shows unstimulated control. Green bars 
show TGF-β2 stimulated cells. Data represent the mean of three experiments. Error 
bars = SEM. 
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Chapter 5 
Discussion 
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Malignant mesothelioma MM is a fatal cancer of the mesothelium (Spugnini et al., 
2006) associated with poor prognosis due to difficulties in diagnosis and the lack of 
treatment options currently available (Chen & Pace., 2012). Therefore, novel 
targeted therapies are required (Kao et al., 2010). Recent studies have focused on the 
role of aberrantly expressed developmental signalling pathways in the pathogenesis 
of several cancers (Dennler et al., 2007: Cigna et al., 2012). Two of these pathways 
are the Hh and TGF-β signalling pathways. There is increasing evidence that these 
pathways work together to promote tumour growth. Some studies have identified 
TGF-β as a potent inducer of the primary Hh effector molecule and transcription 
factor, Gli (Alexaki et al., 2004; Dennler et al., 2007; Javelaud et al., 2012; Mohseny 
et al., 2012). The current study aimed to investigate the interaction of these two 
pathways at the level of Gli, in MM. Identifying new pathways that regulate tumour 
cell growth may lead to the development of novel therapies. 
 
5.1 TGF-β expression in MM cells 
TGF-β is a multifunctional cytokine and has a defined, yet complex role in mediating 
or regulating a series of stochastic events that occur in cancers. (Sporn et al., 1986). 
There are three mammalian isoforms of TGF-β (Massague, 1998). This study 
examined basal mRNA expression levels of the most abundant forms of TGF-β, 
TGF-β1 and TGF-β2 in MM cells. Previous studies have demonstrated substantial 
production of TGF-β isoforms in human and mouse MM cell lines (Gerwin et al., 
1987; Lauber et al., 1992; Fitzpatrick et al., 1994). The effect of blocking 
endogenous TGF-β on MM cell and tumour growth using antisense oligonucleotides 
to TGF-β1 and TGF-β2 showed significant biological effects on MM cell function and 
blocking TGF-β2 inhibited tumour growth in vivo (Fitzpatrick et al., 1994; Marzo et 
al., 1997). Therefore it is clear that TGF-β is an important molecule in MM growth 
but how it mediates it’s effects are not clear. To investigate the interaction between 
TGF-β and Hh signalling I first needed to determine how much of each TGF-β 
isoform was produced in the cells I used in my study.  
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Basal levels of TGF-β1 mRNA was generally expressed higher in control MeT-5A 
cells but had variable expression across the MM cell lines studied compared to 
primary mesothelial cells. Basal levels of TGF-β2 mRNA was generally expressed 
lower in MM and MeT-5A cells compared to primary mesothelial cells. However, 
this study only measured mRNA levels and future studies should also measure 
protein. A previous study examined TGF-β protein in MM tumour tissue by 
immunohistochemistry, and showed differential localisations of TGF-β isoforms, 
where TGF-β1 was shown to be localised more in the stroma than in cells and TGF-
β2 more in MM tumour cells then in the stroma (Jigardar et al., 1997). Although I 
saw more TGF-β1 than TGF-β2 mRNA in the cells this may not reflect protein levels. 
Also, as cells secrete TGF-β in the latent form, immunolocalisation studies would 
only measure total TGF-β and not the amount of active TGF-β present. Therefore a 
more specific type of assay is required which would measure active TGF-β isoforms 
such as enzyme linked immunosorbent assay (ELISA). The assay detects latent TGF-
β, which can then be activated with acids to measure the amount of active TGF-β 
isoform protein present in cell supernatants. In this study, I performed initial 
optimisation experiments using ELISA to measure active and latent TGF-β1 and 
TGF-β2 in MM cells (results not included). However, the latent level was below the 
level of detection. Therefore, this technique needs further optimisation, such as 
concentrating the cell culture supernatants using ultrafiltration approaches. Despite 
only measuring mRNA levels of TGF-β1 and TGF-β2 in this study, the findings show 
that both isoforms are produced by MM cells with possibly more TGF-β1 related to 
malignancy that TGF-β2. However, the importance of TGF-β2 cannot be overlooked 
given that TGF-β2 antisense oligonucleotides blocked MM tumour growth in vivo 
(Marzo et al., 1997). Knowing the basal mRNA levels of TGF-β for each cell line 
also provided a reference point for subsequent experiments. 
 
 
5.2 Gli expression in MM cells 
I also examined the mRNA expression of the Hh signalling pathway effector 
molecules Gli1 and Gli2. Baseline mRNA levels of both Gli1 and Gli2 was variable 
across the MM cell lines and MeT-5A cells had higher Gli1 and Gli2 levels 
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compared to primary mesothelial cells. Although there was variable expression of 
Gli across cell lines, most cells produced Gli mRNA, supporting reports from other 
studies and suggesting a role for Gli and the Hh pathway in MM growth (Shi et al., 
2012; Li et al., 2013). Expression of Gli3 transcription factor mRNA was not 
measured in this study as it is known to be a transcriptional repressor (Matice & 
Joyne, 1999), and other studies have shown a minimal effect of TGF-β on Gli3 
expression (Dennler et al., 2007; Cigna et al., 2012).  
 
5.3 TGF-β signals through the SMAD pathway in MM 
Among the immediate transduction pathways activated by TGF-β, the canonical 
signalling pathway is the SMAD cascade (Massague et al., 2005). SMADs are 
carriers of TGF-β receptor signals into the nucleus and phosphorylation of SMAD2 
and SMAD3 by the TGF-β receptor complex is a critical step in TGF-β ligand 
signalling and transcriptional regulation (Ebner et al., 1993). Binding of TGF-β 
ligand to cell specific receptors activates and phosphorylates TβRI, and this then 
phosphorylates SMAD2 and SMAD3 which form a complex with SMAD4. The 
resulting complex moves to the nucleus and transcription of the target genes is 
achieved (Padgett, 1999).  
I firstly wanted to confirm activity of the human recombinant TGF-β1 and TGF-β2 
preparations used in this study. This was confirmed by phosphorylation of SMAD2 
proteins and its known downstream target gene human collagen type-1α1. TGF-β1 
increased pSMAD2 over time in JU77 cells and also stimulated collagen type-1α1 
mRNA maximally at 24 hr, consistent with previous findings in our laboratory. 
However due to the nature of the total SMAD2/3 antibody used in this project, it was 
difficult to obtain a band each of SMAD2 and SMAD3 proteins by western blotting 
and therefore the quantitation of SMAD2 proteins with imageJ was difficult to 
perform. Similar to the TGF-β1 isoform, TGF-β2 also induced an increase in 
pSMAD2 levels as well as collagen production in MM cells, confirming the activity 
of both TGF-β preparations. To my knowledge, this is also the first time the effect of 
TGF-β2 on pSMAD2 has been examined in MM cells. Interestingly, the maximal 
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fold increase in collagen mRNA induced by TGF-β2 was higher than for TGF-β1. For 
JU77 cells, TGF-β1 stimulated a 2.8 fold increase in collagen mRNA at 24 hr 
compared with a 14 fold increase after TGF-β2 stimulation. This suggests differential 
effects of the two TGF-β isoforms in these cells. 
 
Although western blot analysis showed that TGF-β increased pSMAD2, this 
technique is semi-quantitative, and estimates of protein are prone to factors that may 
alter the final outcomes (Gassman et al., 2009). As a result, better and more 
quantitative measurements of protein changes are required. Recently, a newer 
approach called the Alphacreen® Surefire® assay has been developed to detect these 
proteins in a much more efficient, accurate and timely manner (Hurt & Titus, 2010). 
This assay is a proximity based sandwich immunoassay which uses a combination of 
antibodies, donor beads and acceptor beads, which bind with the target protein 
creating protein complexes that release quantifiable light directly correlating to the 
amount of target protein in that sample (Hurt & Titus, 2010). Several studies have 
successfully optimised and utilised this assay to quantify protein expression in vitro 
(Crouch et al., 2010). Results obtained to date in this study did not reflect the western 
blot data and so most likely needs to be further optimised. However, due to time 
constraints I was unable to fully optimise this technique. 
 
 
5.4 Effect of TGF-β1/2 on Gli1/2 mRNA levels in MM cells. 
The effect of TGF-β1 and TGF-β2 on Gli mRNA expression was then examined in 
MM and control cell lines. TGF-β1 has previously been shown to stimulate an 
increase in Gli2 which in turn upregulates Gli1 in a Gli2-dependent manner (Dennler 
et al., 2007; Cigna et al., 2012).  In glioblastoma, pancreatic adenocarcinoma and 
lung fibroblast cell lines, a rapid induction of Gli2 in response to TGF-β1 was 
observed, peaking between 2-8 hr and levels remaining above basal expression up to 
24 hr, whereas delayed induction of Gli1 was observed between 16-24 hr (Dennler et 
al., 2007; Cigna et al., 2012). Interestingly, TGF-β1 had no effect on either Gli2 or 
Gli1 levels in the 4 MM and control MeT-5A cell lines examined. As MM cells also 
produce TGF-β2 and blocking TGF-β2 inhibits MM tumour growth (Marzo et al, 
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1997), I decided to examine the effect of TGF-β2 on Gli expression. TGF-β2 induced 
Gli2 mRNA between 4-6hr in all MM cell lines and control MeT-5A cells in a 
similar fashion to previous reports for TGF-β1, but interestingly had no effect on Gli1 
mRNA expression up to 48 hr after treatment. 
Previous studies have shown that TGF-β isoforms have a similar structure but serve 
different biological functions in different cell types in vitro and in vivo (Millan et al., 
1991). For example, TGF-β1 gene knockdown mice experience defective 
haematopoiesis and endothelial differentiation, while TGF-β2 null mice exhibit 
cardiac, lung, ear and urogenital defects and TGF-β3 gene ablation mice results in 
delayed pulmonary development (Dunker & Kreiglstein, 2001; Sanford et al., 1997). 
This illustrates diverse biological roles of these isoforms which can influence cell 
growth and differentiation in different cell types in a positive or negative manner 
(Sporn et al., 1986). Thus, despite most studies having shown that TGF-β1 induces 
Gli expression in various cancers, this study showed that TGF-β1 was ineffective in 
inducing Gli in MM cells but TGF-β2 could, highlighting the differential role of the 
two isoforms in respect to Gli activation.  
This differential response may be because it has been reported that TGF-β2 has a 
different mode of receptor activation (Rotzer et al., 2001). As previously described, 
signalling via TGF-β1 is initiated when TGF-β1 binds to TGFβRII, and this recruits 
the binding and phosphorylation of TGFβR1 (Wrana et al., 1994). Activated TGFβRI 
phosphorylates its cytoplasmic effectors SMAD2/3, which phosphorylates and forms 
a complex with SMAD4, translocates to the nucleus and initiates transcription of 
target genes (Massague et al., 1999). In contrast, TGFβRII has a low intrinsic affinity 
for the TGF-β2 isoform (Lin et al., 1995). TGFβRIII or betaglycan acts as a co-
receptor and is required for the responsiveness of TGF-β2, TGFβIII binds to TGF-β2 
and presents it to TGFβRII, and this has been described in different cell types 
(Sankar et al., 1995; Brown et al., 1999). However it is incompletely understood why 
direct binding of TGF-β1 to TGFβRII does not have the same effect (Rotzer et al., 
2001). Therefore, Brown et al. (1999) proposed that TGF-β2 alters the activity and 
composition of TGFβRII-TGFβRI complex in order to activate downstream 
signalling molecules, resulting in specific TGF-β2 effects, and that TGFβRIII has a 
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preferential affinity for the TGF-β2 isoform. Supporting this, an earlier study by 
Mitchell at al. (1992) demonstrated that compared to mesenchymal enriched primary 
placental cells, trophoblast enriched primary placental cell cultures were more 
responsive to TGF-β2 than TGF-β1 due to the presence of an active form of 
betaglycan receptor at the cell surface. Eickelberg and colleagues, (2001) examined 
the function of betaglycan in renal epithelial LLC cells and L6 myoblast cells and 
observed that expression of betaglycan in LLC cells inhibited TGF-β1 signalling, 
measured by collagen expression and phosphorylation of downstream SMAD2/3 
proteins. In comparison, the expression in L6 cells enhanced TGF-β1 signalling. The 
expression of betaglycan in LLC cells prevented association between TGFβRI and 
TGFβRII. Therefore it is possible that in MM cells, betaglycan inhibits TGF-β1 
signalling but supports TGF-β2 signalling by acting as a co-receptor. However, this 
needs to be confirmed by further studies such as measuring the expression of 
TGFβRIII in these cells.   
It was also interesting to note that TGF-β2 induced maximum Gli2 expression in all 
cells lines studied between 4 and 6 hr but the levels then reduced back to basal levels 
at 24 and post TGF-β2 stimulation. These observations are not consistent with the 
findings by Dennler et al. (2007). As previously described, they observed rapid and 
persistent Gli2 induction by TGF-β1, peaking between 2-8 hr and remaining at levels 
higher than their basal expression up to 24 hr. This could possibly be an effect of a 
negative regulator of TGF-β signalling, SMAD7 forming stable complexes with 
active TGF-β receptor complexes and interrupting the phosphorylation of SMAD2/3, 
blocking transcription of target genes (Zhu, Chen & Chen, 2011). Therefore, this 
observation in the current study could mean that although TGF-β2 induces an effect 
on Gli2 expression, this effect could be short lived and may only be functionally 
important in that time frame. Examination of Gli2 target genes at later times might 
suggest functional importance. 
Another interesting observation following TGF-β1 and TGF-β2 treatment in MM 
cells is that Gli1 levels were upregulated in the control 24 hr sample in all cell lines 
examined. A possible reason for this response could be initiation of cell survival 
mechanisms through the Hh signalling pathway. Cells are cultured in 0.4% FCS 
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supplemented medium for 24 hr before and after TGF-β stimulation. Therefore, cells 
are starved of serum and hence growth nutrients for an extended period of time. This 
stress response may in itself stimulate Gli1 expression. The Hh pathway is required 
for growth and survival of tumour cells (Bar et al., 2007). Previous studies showed 
that Hh pathway activation, as evidenced by elevated expression of its target gene 
Gli1, leads to increased transcription of anti-apoptotic molecules such as Bcl-2 in 
medullablastoma (Bar et al., 2007). Other studies have shown that expression of Bcl-
2 is predominantly regulated by Gli2 instead of Gli1, such as in plasmacytoma 
tumour cells (Regl et al., 2004). In this study, induction of Gli expression at 24 hr in 
controls may be a defence mechanism but ultimately masks any increased expression 
of Gli1 at 24 hr in response to TGF-β. This mechanism is worth exploring.  
The functional significance of TGF-β2-induced Gli2 induction can be assessed by 
measuring downstream targets for Gli2. Previous studies have shown Ptch1 to be a 
target gene for Gli1 (Cigna et al., 2012), while others have shown that it is a Gli2 
target (Kim et al., 2007; Regl et al., 2004; Lipinski et al., 2008). Therefore, to 
confirm functional significance of Gli2 activation, the regulation of Ptch1 mRNA 
expression levels were examined in TGF-β2 stimulated CRL2081 and MeT-5A cell 
lines. Ptch1 was upregulated at 48 hr post TGF-β2 stimulation compared to its 
unstimulated control in both cell lines, however only MeT-5A showed significance. 
Although this may be due to the direct effect of Gli2 upregulation, the timing of 
expression of Ptch1 is not consistent with previous reports (Cigna et al., 2012). As 
Gli2 is induced at earlier time points in response to TGF-β2, I expected upregulation 
of Ptch1 at around 24 hr rather than 48 hr if it was a Gli2 target gene in these cells. 
Therefore it is possible that Gli1 was upregulated in response to TGF-β2 at 24 hr and 
hence the delay in upregulation of Ptch1. Clearly this is impossible to confirm when 
control levels of Gli1 were also upregulated after 24 hr with TGF-β2 treatment, but 
this requires further investigation. 
In this study I measured the effect of TGF-β isoforms on Gli mRNA levels rather 
than protein. This was because of difficulty measuring Gli isoforms using currently 
available antibodies for western blot analysis. An alternative approach would have 
been to use a Gli1 or Gli2 reporter assay following TGF-β1/2 treatment. A reporter 
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construct (such as Luciferase) is attached to the gene of interest (Gli1 or Gli2) to 
create gene fusion. This construct is integrated into cellular genomic DNA.  
Following appropriate stimulation there is activation of transcription of the reporter 
gene which releases the reporter protein. In the case of luciferase, this is measured by 
a luminometer, and the intensity of the signal is a direct reflection of the level of 
activity of the gene of interest (Smale, 20010).   
I then wanted to examine the mechanisms regulating TGF-β2-mediated Gli2 
upregulation. To do this I chose two cell lines; MM cell line CRL2081 and control 
MeT-5A (Reddel et al, 1989). Both cell lines were induced by TGF-β2 to up-regulate 
Gli2 mRNA expression. Ideally normal mesothelial cells would have been used as 
controls for all experiments but cultures of normal mesothelial cells were not 
available during the study.  Although TGF-β2 induced Gli2 activation, it was unclear 
if TGF-β2 acted directly on Gli2 or was dependent on the classical Hh Ptch/SMO 
axis. Dennler et al. (2007) showed that cyclopamine abrogated shh induced Gli2 
expression but has no effect on TGF-β1 mediated Gli2 expression. 
However, Cigna et al. (2012) showed that in human lung fibroblasts (HLFs), TGF-β 
induced mRNA and protein expression of α-SMA (Smooth muscle actin), collagen 
and fibronectin. Blocking Hh signalling using cyclopamine inhibited the expression 
of these proteins showing the requirement of Hh signalling in TGF-β-mediated 
expression of certain proteins in these cells. Similarly, Yoo et al. (2008) showed that 
Shh promotes motility and invasiveness of gastric cancer cells through TGF-β-
mediated activation of the ALK5-SMAD3 pathway.   
 
To examine the role of the classic Hh signalling pathway in MM, cells were treated 
with TGF-β2 in the presence or absence of the SMO inhibitor cyclopamine. 
Cyclopamine is a steroidal alkaloid isolated from corn lily, and blocks Hh pathway 
signalling by blocking the Ptch/SMO axis and influencing the function of SMO (Yao 
et al., 2011).  (Ingham & McMahon, 2001). If TGF-β2 was acting through 
Ptch/SMO, then cyclopamine would block the actions of TGF-β2. If not, then 
cyclopamine would have no effect. Studies have analysed the optimal concentration 
of cyclopamine for its ability to block cellular response and thus, 5 and 10µM 
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concentrations were used in this study (Chen et al., 2002; Yao et al., 2011). 
Unfortunately, although I saw a reduction in Gli2 mRNA levels following TGF-β2 
treatment in the presence of cyclopamine, there was an equal reduction in vehicle 
(ethanol) controls. Therefore, no conclusions could be drawn from this study.  Due to 
the unexpected effect of the vehicle control, further optimisation of this experiment 
needs to be performed, possibly using a different vehicle control such as DMSO or 
water, depending on the solubility properties of the cyclopamine preparation. 
Unfortunately there was not enough time available for me to perform these 
optimisation experiments in this study. 
An alternative to measuring Gli2 levels in cyclopamine and TGF-β2 treated 
mesothelial cells is to measure an alternative downstream target gene for Gli such as 
Ptch. As expected, cyclopamine blocked Ptch1 mRNA expression in Met-5A cells, 
but the levels were restored in the presence of TGF-β2. This suggests that TGF-β2 
induces Ptch1 independent of Ptch/SMO-mediated signalling in MeT-5A cells. 
However, this experiment was only performed once and only in MeT-5A cells. 
Therefore these findings need to be confirmed and the effect on MM cells examined. 
 
 
5.5 SB-431542 inhibits TGF-β2-induced Gli2 expression in MM cells. 
I then wanted to determine if TGF-β2 was stimulating Gli2 mRNA upregulation 
through the classic TGF-β signalling receptor TβRI/ALK5 via the SMAD signalling 
pathway. The TGF-β ligand brings together type 1 and type II receptor complexes. 
The type II receptor phosphorylates and activates the type I receptor (ALK5) 
(Moustakas et al., 1993) and the signals are transduced to the nucleus primarily 
through activation of the SMAD2/3 complex (Ebner et al., 1993). To assess the role 
of the ALK5 receptor in TGF-β2-mediated Gli2 expression, I measured TGF-β2-
induced Gli2 mRNA expression after blocking TGF-β2 signalling using the ALK5 
inhibitor SB-431542. This is a potent inhibitor of the ALK5 receptor that acts as a 
competitive ATP binding site kinase inhibitor, and has been shown to inhibit the in 
vitro phosphorylation of SMAD2 and SMAD3 (Inham et al., 2002). To examine the 
effectiveness of this inhibitor, cells were pretreated with SB-431542 followed by 
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TGF-β2 stimulation. TGF-β2 alone increased phosphorylation of SMAD2 in both 
CRl2081 and MeT-5A cells. However, in the presence of SB431542, pSMAD2 
induction by TGF-β2 was prevented. Consequently, TGF-β2-induced Gli2 was also 
inhibited by SB-431542. Therefore it was concluded that TGF-β2 acts through the 
ALK5 receptor to induce Gli2 mRNA expression.   
 
5.6 TGF-β2-induced Gli2 is mediated throught the SMAD2/3 signalling cascade. 
I then wanted to determine if TGF-β2-induced Gli2 was mediated through SMAD2/3 
signalling. Western blot data clearly showed that TGF-β2 induced pSMAD2/3 in MM 
and MeT-5A cells. However, TGF-β can also signal through other pathways such as 
MAPK and PI3K. The approach I used was to block SMAD2 and SMAD3 using 
specific siRNA and measure its effect on TGF-β2-mediated Gli2 expression.  
 
I first tested the transfection efficiency of this approach. Unfortunately, the siRNA 
available to SMAD2 and SMAD3 were not tagged with a reporter molecule and so I 
could not work out the efficiency directly from my SMAD transfection studies. 
Therefore, I used an FITC labelled scrambled siRNA. Both cell lines demonstrated a 
low percentage of cells carrying the label, with only 6% efficiency in CRL2081 cells 
and 25% in MeT-5A. The experiment was performed using live cell harvest for 
FACS analysis which would compromise the mortality of cells and the transfection 
efficiency. Therefore, this low transfection efficiency could be due to technical issues 
when performing the experiment such as extended spinning time, or delay during cell 
harvest. If I had more time I would optimize the technique with other harvesting and 
cell fixing techniques before FACS analysis to avoid technical issues and get a better 
readout.  
 
Despite the relatively low transfection efficiency, I tried to obtain effective mRNA 
and protein knockdown of pSMAD2 and total SMAD2/3 using SMAD2 and SMAD3 
siRNA at a range of concentrations. The 1 nM concentration had limited effect, 
whereas I got significant knockdown at 10 and 20 nM siRNA although at 20 nM 
some of the effects may have been non-specific. Previous studies have shown that 
  
 
116 
high concentrations of siRNA can have off-target effects and relatively low 
concentrations (e.g 1 nM) are sufficient to silence the intended target (Caffrey et al., 
2011). The 10 nM siRNAs led to efficient knockdown at the mRNA and protein 
level, and therefore this concentration was used for subsequent experiments. siRNA 
to SMAD2 and SMAD3, individually and combined, effectively knocked down 
SMAD2 and SMAD3 mRNA and protein phosphorylation in both CRL2081 and 
MeT-5A cells in the presence or absence of TGF-β2, with the greatest effect when the 
SMAD2 and SMAD3 siRNA were combined. However, as the transfection 
efficiency in CRL2081 cells was so low, it is unclear if this result was real or non 
specific. Further optimisation studies are needed to confirm siRNA results in 
CRL2081 cells. Analysis of Gli2 mRNA levels following TGF-β2 stimulation in cells 
transfected with SMAD2 and SMAD3 siRNA, clearly showed suppression of TGF-
β2-mediated Gli2 mRNA, confirming the role of the SMAD pathway. These results 
are consistent with the findings by Dennler et al. (2007) where they showed that 
SMAD3 siRNA markedly impaired TGF-β-induced Gli2 mRNA expression in 
fibroblasts and keratinocytes. 
 
5.7 Summary and Conclusions 
 
MM remains a disease with a dismal outcome. Hh and TGF-β signalling pathways 
are involved in numerous overlapping processes during development and recent 
studies have discovered this interaction may be important in the pathogenesis of 
some cancers (Perrot et al., 2013; Javelaud et al., 2012; Dennler et al., 2007). 
Therefore the role of this interaction in diagnosis, prognosis and treatment options in 
MM have to be investigated. This study aimed to determine whether this pathway 
interaction occurs in MM, particularly if TGF-β induces the Gli transcription factors.  
 
TGF-β1/2 isoforms and Gli1/2 are variably expressed in MM cell lines. TGF-β1 had 
no effect on Gli1 or Gli2 expression. However, TGF-β2 induced Gli2 but not Gli1 
mRNA expression. Both TGF-β1 and TGF-β2 signals through the canonical SMAD 
signalling pathway and blocking TGF-β2 signalling at the TβRI receptor level 
inhibited TGF-β2 mediated Gli2 mRNA expression and pSMAD2 protein expression. 
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Knocking down SMAD2/3 using siRNA also inhibited increased TGF-β2-mediated 
Gli2 mRNA levels, confirming the role of the SMAD2/3 signalling pathway in TGF-
β2-mediated Gli2 upregulation. However, it is yet to be determined if TGF-β2-
mediated Gli2 activation is independent of Hh signalling, and if this interaction plays 
a functional role in MM tumour growth.  
 
From the results of this study, it can be concluded that TGF-β2 is a potent inducer of 
Gli2 and mediates its effects through the SMAD2/3 signalling pathway. Although 
further studies are required to determine that targeting TGF-β/Gli interaction may 
provide therapeutic benefits for MM patients. 
 
5.8 Future directions 
This study has confirmed the interaction of TGF-β with Hh signalling pathway 
effector molecules Gli, but further studies are required to delineate the signalling 
mechanisms and elucidate the biological significance of this interaction. The current 
study was limited by only examining this interaction at the level of Gli mRNA. 
Therefore to further address the interaction of Hh and TGF-β signalling pathways, 
the study needs to be expanded to investigate the role of TGF-β1/2 on Gli1/2 protein 
levels and on other Hh mediators such as Ptch1, Ptch2, SMO and Hhip and their 
downstream target genes, and how this may contribute to TGF-β2 mediated tumour 
growth.  
 
It would also be valuable to examine the role of TGF-β2-induced Gli2 and the 
expression of its downstream target genes in MM. Also, the functional effect of 
TGF-β2-induced Gli2 on cell proliferation, differentiation, viability, apoptosis, 
migration and invasion. This study also needs to be expanded to investigate the 
failure of TGF-β1/2 to induce Gli1 using other methods and assays, and subsequently 
the functional significance of TGF-β2-mediated effects compared with TGF-β1-
mediated effects reported by others. To determine if TGF-β2 mediated Gli2 induction 
is dependent or independent of Hh signalling, the cyclopamine experiment should be 
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further optimised, as well as examining the effect of other Hh signalling inhibitors on 
TGF-β2-induced Gli2 for comparison. 
 
Further studies should also investigate the effect of exogenous TGF-β2 on Gli2 
expression and the effects of blocking this activation in vivo. A murine model would 
provide the opportunity to assess the role of this pathway interaction in vivo tumour 
growth. To achieve this, MM cell lines could be transfected with adenoviral vectors 
expressing single or combinations of active TGF-β2, SMAD2 or SMAD3 siRNA or 
control constructs and transplanted into mice or treated with a Gli inhibitor such as 
GANT61 (Mazumdar et al., 2011), and tumour formation compared. The animals 
would be killed at various times or once the tumour reached 1 cm in diameter, and 
Hh pathway mediators such as Gli1, Gli2, Ptch1, Ptch2, Smo and Hhip levels 
measured as well as features such as histopathology, cell proliferation and apoptosis.   
 
Interfering with TGF-β2 signalling has shown promising results in preventing tumour 
growth in a variety of tumour types including MM. Similarly, the effect of combined 
TGF-β and Gli inhibitors need to be investigated in vitro and in vivo in MM to define 
effective therapeutic strategies.  
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